06 October 2023
EMA/CHMP/353930/2023
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 17-20 July 2023

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this set of minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The CHMP was reminded that as of July 2023, the CHMP plenary meetings are either fully remotely, or in-person at the EMA premisses in Amsterdam. For in-person meetings, members are required to attend physically. Members participating remotely are not allowed to participate in votes nor elections in accordance with the CHMP rules of procedure. However, they can be represented by their alternate or give a proxy to another CHMP member attending the meeting in person.

1.2. Adoption of agenda

CHMP agenda for 17-20 July 2023.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 19-22 June 2023.

The CHMP adopted the CHMP minutes for 19-22 June 2023.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 10 July 2023.

The CHMP adopted the minutes from the PROM meeting held on 10 July 2023.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. quizartinib - Orphan - EMEA/H/C/005910

Daiichi Sankyo Europe GmbH; Treatment of adult patients with diagnosed acute myeloid leukaemia (AML)

Scope: Oral explanation

Action: Oral explanation to be held on 18 July 2023 at 16:00

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.2. Re-examination procedure oral explanations

2.2.1. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

Orexigen Therapeutics Ireland Limited

Scope: "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly."

Opinion on the request for re-examination

Oral explanation

Action: Oral explanation to be held on 18 July 2023 at 09:00

Opinion adopted on 30.03.2023. Request for Supplementary Information adopted on 26.01.2023, 15.09.2022, 24.03.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 9.1

2.3. Post-authorisation procedure oral explanations

2.3.1. Bylvay - odevixibat - Orphan - EMEA/H/C/004691/II/0011

Albireo

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

"Extension of indication to include the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older for Bylvay, based on final results from study A4250-012 and interim results from study A4250-015. Study A4250-012 is a 24-week, randomised, double-blind, placebo-controlled Phase III study conducted in 52 patients with a genetically confirmed diagnosis of ALGS and presence of pruritus and high serum bile acid levels at baseline. Study A4250-015 is an ongoing 72-week open-label extension trial for patients who completed study A4250-012 and evaluates the long-term safety and efficacy of Bylvay in patients with ALGS. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and Annex II of the Marketing Authorisation are updated. The Package Leaflet is updated in accordance. Version 2.4 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet, Annex II and to the Risk Management Plan (RMP)."

Scope: Oral explanation

Action: Oral explanation to be held on 18 July 2023 at 14:00

Request for Supplementary Information adopted on 22.06.2023, 30.03.2023.

An oral explanation was held on 18 July 2023. The presentation by the MAH focused on the clinical data in support of the application.

See 5.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Abrysvo - respiratory syncytial virus vaccines - EMEA/H/C/006027

Accelerated assessment

Pfizer Europe MA EEIG; prevention of respiratory tract disease

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.06.2023. List of Questions adopted on 24.04.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that RSV subgroup A glycoprotein F and RSV subgroup B glycoprotein F, stabilised in prefusion conformation and produced in Chinese Hamster Ovary cells by recombinant DNA technology, is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.2. Apretude - cabotegravir - EMEA/H/C/005756

ViiV Healthcare B.V.; pre-exposure prophylaxis of HIV-1 infection

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 23.02.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.3. Degarelix Accord - degarelix acetate - EMEA/H/C/006048

Accord Healthcare S.L.U.; treatment of prostate cancer

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Firmagon

List of Outstanding Issues adopted on 26.04.2023. List of Questions adopted on 10.11.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.4. Enrylaze - crisantaspase - EMEA/H/C/005917

Jazz Pharmaceuticals Ireland Limited; Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 13.10.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 18 July 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.5. Inaqovi - decitabine / cedazuridine - EMEA/H/C/005823

Otsuka Pharmaceutical Netherlands B.V.; treatment of myeloid leukaemia

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that cedazuridine is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.6. Krazati - adagrasib - EMEA/H/C/006013

Mirati Therapeutics B.V.; treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023, 23.02.2023. List of Questions adopted on 15.09.2022.

The Committee adopted a negative opinion by majority (31 negative out of 32 votes) recommending the refusal of the granting of the conditional marketing authorisation for the above-mentioned medicinal product.

The divergent position (Kristina Dunder) was appended to the opinion.

The refusal question-and-answer document was circulated for information.

3.1.7. Litfulo - ritlecitinib - EMEA/H/C/006025

Pfizer Europe MA EEIG; Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that ritlecitinib is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.8. Lyfnua - gefapixant - EMEA/H/C/005476

Merck Sharp & Dohme B.V.; treatment of refractory or unexplained chronic cough

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.06.2023, 26.04.2023, 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that gefapixant is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.9. Orserdu - elacestrant - EMEA/H/C/005898

Stemline Therapeutics B.V.; Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that elacestrant is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 10 July 2023.

The summary of opinion was circulated for information.

3.1.10. Talvey - talquetamab - PRIME - Orphan - EMEA/H/C/005864

Janssen-Cilag International N.V.; monotherapy treatment of adult patients with relapsed and refractory multiple myeloma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.06.2023. List of Questions adopted on 24.04.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that talquetamab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 18 July 2023.

The summary of opinion was circulated for information.

3.1.11. Tepkinly - epcoritamab - Orphan - EMEA/H/C/005985

AbbVie Deutschland GmbH & Co. KG; treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 23.02.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that epcoritamab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.12. Tevimbra - tislelizumab - Orphan - EMEA/H/C/005919

Novartis Europharm Limited; Tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 30.03.2023. List of Questions adopted on 21.07.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that tislelizumab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.13. Tyenne - tocilizumab - EMEA/H/C/005781

Fresenius Kabi Deutschland GmbH; treatment of rheumatoid arthritis, active systemic juvenile idiopathic arthritis (sJIA), juvenile idiopathic polyarthritis (pJIA), Giant Cell Arteritis (GCA), treatment of rheumatoid arthritis, chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS) and COVID-19

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 18 July 2023.

The summary of opinion was circulated for information.

3.1.14. Tyruko - natalizumab - EMEA/H/C/005752

Sandoz GmbH; Therapy for active relapsing remitting multiple sclerosis (RRMS)

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.06.2023, 26.04.2023. List of Questions adopted on 10.11.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.15. Yesafili - aflibercept - EMEA/H/C/006022

Viatris Limited; treatment of age-related macular degeneration (AMD) and visual impairment

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.09.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 7 July 2023.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. vamorolone - Orphan - EMEA/H/C/005679

Santhera Pharmaceuticals (Deutschland) GmbH; Treatment of Duchenne muscular dystrophy (DMD)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.02.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. lebrikizumab - EMEA/H/C/005894

Treatment of moderate-to-severe atopic dermatitis in adults and adolescents

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.02.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. trastuzumab duocarmazine - EMEA/H/C/005654

treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 10.11.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP did not agree to the request by the applicant for an extension to the clock stop but agreed to a shorter extension with a specific timetable.

3.2.4. leniolisib - Orphan - EMEA/H/C/005927

Pharming Technologies B.V.; Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.01.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult an ad-hoc expert group and adopted a list of questions to this group.

3.2.5. pegzilarginase - Orphan - EMEA/H/C/005484

Immedica Pharma AB; treatment of hyperargininemia

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.12.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. rezafungin - Orphan - EMEA/H/C/005900

Mundipharma GmbH; treatment of invasive candidiasis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.12.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. quizartinib - Orphan - EMEA/H/C/005910

Daiichi Sankyo Europe GmbH; Treatment of adult patients with diagnosed acute myeloid leukaemia (AML)

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 15.12.2022.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.8. palopegteriparatide - Orphan - EMEA/H/C/005934

Ascendis Pharma Bone Diseases A/S; PTH replacement therapy indicated for the treatment of hypoparathyroidism in adults.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. apremilast - EMEA/H/C/006208

treatment of psoriatic arthritis, psoriasis, Behçet's disease

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. axitinib - EMEA/H/C/006206

treatment of adult patients with advanced renal cell carcinoma (RCC)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. bimatoprost - EMEA/H/C/005916

indicated for the reduction of intraocular pressure (IOP) in adults with open angle glaucoma (OAG) or ocular hypertension (OHT) who are unsuitable for topical IOP-lowering medications.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. serplulimab - Orphan - EMEA/H/C/006170

Henlius Europe GmbH; first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. pomalidomide - EMEA/H/C/006195

in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma (MM)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. flortaucipir (18F) - EMEA/H/C/006064

indicated for Positron Emission Tomography (PET) imaging of the brain

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. danicopan - PRIME - Orphan - EMEA/H/C/005517

Alexion Europe; Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. retifanlimab - Orphan - EMEA/H/C/006194

Incyte Biosciences Distribution B.V.; Treatment of Merkel cell carcinoma (MCC).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165

indicated for in vitro labelling of kits for radiopharmaceutical preparation

Scope: Letter by the applicant dated 30.06.2023 requesting an extension to the clock stop to respond to the list of questions adopted in December 2021

Action: For adoption

List of Questions adopted on 16.12.2021.

The CHMP did not agree to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in December 2021.

3.4.2. Lutholaz - pegfilgrastim - EMEA/H/C/005587

YES Pharmaceutical Development Services GmbH; treatment of neutropenia

Scope: Letter by the applicant dated 12.07.2023 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in April 2023.

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 26.04.2023. List of Questions adopted on 24.02.2022.

The CHMP did not agree to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2023.

See 3.7

3.4.3. dopamine hydrochloride - PUMA - EMEA/H/C/006044

Treatment of hypotension in neonates, infants and children

Scope: Letter by the applicant requesting an extension to the clock stop to respond to the list of questions adopted in March 2023.

Action: For adoption

List of Questions adopted on 30.03.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in March 2023.

3.4.4. nintedanib - EMEA/H/C/006179

treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) and lung diseases (ILDs) systemic sclerosis associated interstitial lung disease (SSc-ILD)

Scope: Letter by the applicant dated 04.07.2023 requesting an extension to the clock stop to respond to the list of questions adopted in April 2023.

Action: For adoption

List of Questions adopted on 26.04.2023.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in April 2023.

3.4.5. paclitaxel - EMEA/H/C/005997

treatment of metastatic breast cancer

Scope: Letter by the applicant requesting an extension to the clock stop to respond to the list of outstanding issues in October 2022.

Action: For adoption

List of Outstanding Issues adopted on 13.10.2022. List of Questions adopted on 19.05.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues in October 2022.

3.4.6. efbemalenograstim alfa - EMEA/H/C/005828

Reduction in the duration of neutropenia and the incidence of febrile neutropenia.

Scope: Letter by the applicant dated 17.02.2023 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in July 2022.

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 27.01.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in July 2022.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Albrioza - sodium phenylbutyrate / ursodoxicoltaurine - Orphan - EMEA/H/C/005901

Amylyx Pharmaceuticals EMEA B.V.; treatment of amyotrophic lateral sclerosis (ALS)

Scope: Re-examination rapporteur appointment

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion on 22.06.2023. List of Outstanding Issues adopted on 23.02.2023, 10.11.2022. List of Questions adopted on 23.06.2022.

The Committee appointed a re-examination rapporteur and a re-examination co-rapporteur.

3.5.2. Lagevrio - molnupiravir - EMEA/H/C/005789

Merck Sharp & Dohme B.V.; treatment of coronavirus disease 2019 (COVID-19)

Scope: Withdrawal of re-examination request; Q&A document

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 23.02.2023. List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 24.02.2022, 16.12.2021.

The CHMP noted the withdrawal of the re-examination request.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Jesduvroq - daprodustat - EMEA/H/C/005746

Glaxosmithkline Trading Services Limited; treatment of anaemia associated with chronic kidney disease (CKD) in adults

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 22.06.2023. List of Outstanding Issues adopted on 25.05.2023, 30.03.2023, 10.11.2022. List of Questions adopted on 23.06.2022.

The CHMP noted the withdrawal of the marketing authorisation application.

3.7.2. Gefzuris - gefapixant - EMEA/H/C/005884

Merck Sharp & Dohme B.V.; treatment of refractory or unexplained chronic cough

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC), Duplicate of Lyfnua

List of Outstanding Issues adopted on 22.06.2023, 26.04.2023, 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP noted the withdrawal of the marketing authorisation application.

3.7.3. Lutholaz - pegfilgrastim - EMEA/H/C/005587

YES Pharmaceutical Development Services GmbH; treatment of neutropenia

Scope: Withdrawal of marketing authorisation application

Action: For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 26.04.2023. List of Questions adopted on 24.02.2022.

See 3.4

The CHMP noted the withdrawal of the marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/X/0016

Novo Nordisk A/S

Rapporteur: Daniela Philadelphy

Scope: "Extension application to add two new strengths of 4000 IU and 5000 IU powder and solvent for solution for injection."

Action: For adoption

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 26.01.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendation dated 13 July 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment.

4.1.2. Olumiant - baricitinib - EMEA/H/C/004085/X/0035/G

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension application to introduce a new strength (1 mg film-coated tablet), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment, as monotherapy or in combination with conventional synthetic disease modifying antirheumatic drugs (DMARDs), of active juvenile idiopathic arthritis (JIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs, based on final results from the pivotal

study JAHV (I4V-MC-JAHV); this is a multicentre, double-blind, randomised, placebo-controlled, medication-withdrawal Phase 3 study in children from 2 years to less than 18 years of age with JIA who have had an inadequate response or intolerance to treatment with at least 1 cDMARD or bDMARD. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 15.1 of the RMP has also been submitted."

Action: For adoption

List of Outstanding Issues adopted on 25.05.2023. List of Questions adopted on 26.01.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Kaftrio - ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA/H/C/005269/X/0033

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new pharmaceutical form (granules) associated with 2 new strengths (60 mg/40 mg/80 mg and 75 mg/50 mg/100 mg) to support a new indication in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene (see section 5.1). The new indication is only applicable to the new granules pharmaceutical form. As a consequence of the line extension, the PI for the film coated tablets is also updated to reflect the addition of a new pharmaceutical form.
The RMP (version 6.2) has also been submitted."

Action: For adoption

List of Questions adopted on 26.04.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to non-clinical and clinical aspects as well as the RMP.

The Committee adopted a list of outstanding issues with a specific timetable.

4.2.2. Kalydeco - ivacaftor - EMEA/H/C/002494/X/0114/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Beata Maria Jakline Ullrich, PRAC Rapporteur: Monica Martinez Redondo

Scope: "Extension application to add a new strength (59.5 mg) of the granules pharmaceutical form grouped with C.I.6.a, to support a new indication in a combination

regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene (see section 5.1).
The RMP (version 15.1) has also been submitted.
Type IB B.II.f.1.b
The Product information has been updated accordingly."

Action: For adoption

List of Questions adopted on 26.04.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to clinical aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

4.2.3. Takhzyro - lanadelumab - Orphan - EMEA/H/C/004806/X/0034/G

Takeda Pharmaceuticals International AG Ireland Branch

Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension application to add a new strength of 150 mg for lanadelumab solution for injection in pre-filled syringe and to extend the indication to include paediatric use (2 to <12 years). The new indication is only applicable to the new 150 mg strength presentations.
The RMP (version 3.0) is updated in accordance.
A type IB variation (C.I.z) has been submitted to update section 7 of the Package Leaflet (PL) for the 300 mg in 2 ml pre-filled syringe (EU/1/18/1340/004-006) in line with the proposed PL for the 150 mg in 1 ml pre-filled syringe (new strength).
In addition, the MAH has requested an extension of the Orphan Market Exclusivity from 10 to 12 years."

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to quality and clinical aspects as well as the RMP.

The Committee adopted a list of outstanding issues with a specific timetable.

4.2.4. Tecentriq - atezolizumab - EMEA/H/C/004143/X/0076

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (1875 mg) and new route of administration (subcutaneous use). The RMP (version 24.0) is updated in accordance."

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to clinical aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

4.2.5. Vyvgart - efgartigimod alfa - Orphan - EMEA/H/C/005849/X/0003

Argenx

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (1000 mg) and a new route of administration (subcutaneous use)."

Action: For adoption

List of Questions adopted on 30.03.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues, relating to quality and clinical aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Skyrizi - risankizumab - EMEA/H/C/004759/X/0033

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Finbarr Leacy

Scope: "Extension application to add a new strength of 90 mg solution for injection in pre-filled syringe, indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Teriflunomide Accord - teriflunomide - EMEA/H/C/005960/X/0002

Accord Healthcare S.L.U.

Rapporteur: Kristina Nadrah, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new strength of 7 mg film-coated tablets. The bioequivalence study data were submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0012

Pfizer Europe MA EEIG

Rapporteur: Daniela Philadelphy, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication to include infants, children and adolescents from 6 weeks to less than 18 years of age for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae, based on final results from studies B7471003, B7471011, B7471012, B7471013 and B7471014. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.2. Aspaveli - pegcetacoplan - Orphan - EMEA/H/C/005553/II/0011

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Alexandre Moreau, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor for Aspaveli, based on final results from study APL2-308. This is a Phase III, randomized, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Beyfortus - nirsevimab - EMEA/H/C/005304/II/0005

AstraZeneca AB

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of children up to 24 months of age who remain vulnerable to severe Respiratory Syncytial Virus (RSV) disease through their second RSV season for Beyfortus, based on interim results from studies D5290C00005 and D5290C00008.
Study D5290C00005 (MEDLEY) is a Phase II/III, randomized, double-blind, placebo-controlled study to evaluate the safety of Beyfortus in high-risk children. Study D5290C00008 (MUSIC) is a Phase II, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetics, and occurrence of antidrug antibody for Beyfortus in immunocompromised children ≤ 24 Months of Age.
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 2.1 of the RMP has also been submitted.
In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical apects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.4. Bylvay - odevixibat - Orphan - EMEA/H/C/004691/II/0011

Albireo

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older for Bylvay, based on final results from study A4250-012 and interim results from study A4250-015. Study A4250-012 is a 24-week, randomised, double-blind, placebo-controlled Phase III study conducted in 52 patients with a genetically confirmed diagnosis of ALGS and presence of pruritus and high serum bile acid levels at baseline. Study A4250-015 is an ongoing 72-week open-label extension trial for patients who completed study A4250-012 and evaluates the long-term safety and efficacy of Bylvay in patients with ALGS. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and Annex II of the Marketing Authorisation are updated.

The Package Leaflet is updated in accordance. Version 2.4 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet, Annex II and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023, 30.03.2023.

See 2.3

An oral explanation was held on 18 July 2023. The presentation by the MAH focused on the clinical data in support of the application.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.5. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0027

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: "Extension of indication to include the indication treatment of non-small cell lung cancer for Enhertu (trastuzumab deruxtecan), based on results from study DS8201-A-U204 (DESTINY-Lung01) and study DS8201-A-U206 (DESTINY-Lung02).
Study DESTINY-Lung01 is a phase 2, multicentre, open-label, 2-cohort study of trastuzumab deruxtecan (DS-8201a), an anti-HER2 antibody drug conjugate (ADC), for HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer (NSCLC) conducted at sites in Japan, the United States and Europe.
Study DESTINY-Lung02 is an ongoing phase 2, multicentre, randomised study to evaluate the safety and efficacy of trastuzumab deruxtecan in subjects with HER2-mutated metastatic non-small cell lung cancer, conducted in North America, Europe and Asia-Pacific.
As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.6. Ervebo - recombinant vesicular stomatitis virus - Zaire Ebolavirus vaccine (live) - EMEA/H/C/004554/II/0025

Merck Sharp & Dohme B.V.

Rapporteur: Christophe Focke, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the paediatric population from 1 year to less than 18 years of age based on final results from study V920-016 (PREVAC); this is a phase 2, randomised, double-blind, placebo-controlled study of 2 leading Ebola vaccine candidates

(Ad26.ZEBOV/MVA-BN-Filo and V920) and 3 vaccine strategies (Ad26.ZEBOV/MVABN-Filo, 1-dose V920, and 2 dose V920) to evaluate immunogenicity and safety in healthy children and adolescents from 1 to 17 years of age and adults 18 years of age and older. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been approved. In addition, the MAH took the opportunity to update the Annex II and the list of local representatives in the Package Leaflet.
The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP)."

Action: For adoption

Request for Supplementary Information adopted on 26.04.2023, 10.11.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.7. Evrysdi - risdiplam - Orphan - EMEA/H/C/005145/II/0005/G

Roche Registration GmbH

Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Jan Neuhauser

Scope: "Grouping of three variations as follows:
Extension of indication to include treatment of patients below 2 months of age based on interim results from study BN40703 (RAINBOWFISH). The pivotal study RAINBOWFISH is an ongoing phase II multicentre, open-label, and single-arm study designed to evaluate the efficacy, safety, tolerability, and PK/PD of risdiplam in pre-symptomatic infants below 2 months of age who were genetically diagnosed with SMA. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to make some editorial improvements in the product information. A revised RMP version 1.1 was also submitted as part of the application.
Type IAIN, B.IV.1.a.1 variation to update Evrysdi pack configuration with the addition of a new 1 mL oral syringe into the product carton allowing precise dosing of infants below 2 months of age. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance.
Type IAIN, B.IV.1.b variation to remove the spare unit of 12 mL oral syringe out of the two units currently provided in the product carton. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 13.10.2022, 21.07.2022, 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.8. Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0043

Seqirus Netherlands B.V.

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication to include adults 50 years of age and older for Fluad Tetra, based on final results from study V118_23; this is a phase 3, randomized, observer-blind, controlled, multicenter, clinical study to evaluate immunogenicity and safety of an MF59-adjuvanted quadrivalent subunit inactivated influenza vaccine in comparison with a licensed quadrivalent influenza vaccine, in adults 50 to 64 years of age. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. Version 2.9 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. Foclivia - pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/001208/II/0081

Seqirus S.r.l

Rapporteur: Maria Grazia Evandri, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include children from 6 months to less than 18 years of age for Foclivia, based on final results from study V87_30; this is a phase 2, randomized, observer-blind, multicenter study to evaluate the immunogenicity and safety of several doses of antigen and MF59 adjuvant content in a monovalent H5N1 pandemic influenza vaccine in healthy pediatric subjects 6 months to less than 9 years of age. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 4.9 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to bring it in line with the latest QRD template."

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023, 30.03.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.10. Imfinzi - durvalumab - EMEA/H/C/004771/II/0057

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include Imfinzi as treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from study D419CC00002 (HIMALAYA); this was a randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (HIMALAYA). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9, Succession 1 of the RMP has also been submitted. In addition, the PI is brought in line with the latest QRD template version 10.3."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.11. Jardiance - empagliflozin - EMEA/H/C/002677/II/0076

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication for Jardiance to include treatment of children aged 10 years and above with type 2 diabetes based on results from study DINAMO 1218-0091; this is a double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 21.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 26.04.2023.

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.12. Jemperli - dostarlimab - EMEA/H/C/005204/II/0023

GlaxoSmithKline (Ireland) Limited

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Inês Ribeiro-Vaz

Scope: "Extension of indication to include in combination with platinum-containing chemotherapy the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer

(EC) and who are candidates for systemic therapy, based on results from study 213361 (RUBY) Part 1, listed as a Specific Obligation in the Annex II; this is a phase 3, randomized, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.13. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0133

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma for Keytruda, based on interim results from study KEYNOTE-811, an ongoing Phase 3, double-blind trial comparing trastuzumab plus chemotherapy and pembrolizumab with trastuzumab plus chemotherapy and placebo as first-line treatment in participants with HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Annex II, Package Leaflet and Labelling are updated in accordance. Version 38 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.14. Livmarli - maralixibat - Orphan - EMEA/H/C/005857/II/0003/G

Mirum Pharmaceuticals International B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Adam Przybylkowski

Scope: "Grouped variation consisting of:
1) Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 2 months of age and older for Livmarli, based on results from

studies MRX-502, LUM001-501, MRX-503, MRX-800 and MRX-801; MRX-502 is an international, multicenter, randomized, double-blind, placebo-controlled, parallel group Phase 3 study that evaluated the efficacy and safety of maralixibat in PFIC participants aged >12 months to <18 years on a proposed dosage of up to 600 µg/kg BID over 6 months. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Annex II are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes.
2) B.I.b.1.b - type IA
In addition, further editorial changes are made in module 3 which are consequential to the extension of indication and the higher maximum daily dose." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.15. Olumiant - baricitinib - EMEA/H/C/004085/II/0037

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include the treatment of paediatric patients (from 2 years of age and older) with moderate to severe atopic dermatitis for Olumiant, based on the final results from study I4V-MC-JAIP; this is a Phase III, multicentre, randomised, double blind, placebo controlled, parallel-group, outpatient study evaluating the pharmacokinetics, efficacy, and safety of baricitinib in paediatric patients with moderate-to-severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet has been updated accordingly. Version 17.1 of the RMP has also been submitted".

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to clinical aspects and the RMP.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.16. Opdivo - nivolumab - EMEA/H/C/003985/II/0130

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include Opdivo for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, based on results from study CA20976K; This is a phase III, randomized, double-blind study of adjuvant immunotherapy with nivolumab versus placebo

after complete resection of stage IIB/C melanoma. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 33.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.17. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0021

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting for Retsevmo based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumors. LIBRETTO-121 is a Phase 1/2 study of selpercatinib in paediatric patients with advanced RET-altered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.18. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0022

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Retsevmo to include the treatment of adults with advanced or metastatic RET fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no satisfactory therapeutic options, based on interim data from study LIBRETTO-001 (LOXO-RET-17001); LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial

changes to the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.19. Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0104/G

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Grouped variation:
C.I.6.a: Extension of indication to include the use of Spikevax bivalent Original/Omicron BA.4-5 (50 micrograms/50 micrograms)/mL dispersion for injection in children 6 months through 4 years of age, based on data from study mRNA-1273-P306 (NCT05436834) part 1; this is an Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 (Original/Omicron BA.1) vaccine for SARS-CoV-2 in participants aged 6 months to < 6 years; as a consequence, sections 4.1 and 4.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.1 of the RMP has been approved.
C.I.6.a: Extension of indication to include the use of Spikevax bivalent Original/Omicron BA.4-5 (all presentations) as a single-dose in individuals 5 years of age and older, irrespective of their vaccination history, based on epidemiology and clinical data from study mRNA-1273-P306; as a consequence, section 4.2 of the SmPC is updated. The Package Leaflet is updated in accordance.
In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes throughout the SmPC, Annex II, labelling and package leaflet."

Action: For adoption

Request for Supplementary Information adopted on 22.06.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Iclusig - ponatinib - Orphan - EMEA/H/C/002695/II/0064

Incyte Biosciences Distribution B.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ulla

Wändel Liminga

Scope: "Extension of indication to include treatment of newly diagnosed adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), either with Iclusig (ponatinib) in combination with chemotherapy, or with Iclusig (ponatinib) monotherapy after corticosteroid induction in patients not eligible to receive chemotherapy-based regimens, based on final results from studies AP24534-11-001 and INCB 84344-201. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 26.04.2023, 10.11.2022.

The CHMP noted the update.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

6.1.1. gentamicin sulfate / sargramostim / heparin sodium / insulin human - EMEA/H/D/006090

human assisted reproductive techniques including in-vitro fertilisation procedures

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 30.03.2023. List of Questions adopted on 13.10.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006232

to detect rearrangements involving the ALK gene via fluorescence

Scope: Opinion

Action: For adoption

List of Questions adopted on 22.06.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. Avibactam sodium, Aztreonam – OPEN – H0006113

treatment of adult patients with infections caused by Gram-negative bacteria for which there are limited or no treatment options.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. Garadacimab - Orphan - H0006116

CSL Behring GmbH; Indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.3. donanemab – H0006024

Donanemab is indicated to slow disease progression in patients with early symptomatic Alzheimer's disease. Treatment with donanemab should be initiated in patients with evidence of AD neuropathology and either mild cognitive impairment or mild dementia

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.4. sotatercept - Orphan - H0005647

Merck Sharp & Dohme B.V., indicated for the treatment of pulmonary arterial hypertension (PAH) in adult patients on standard of care with WHO Functional Class (FC) II to III, to improve exercise capacity, provide clinical improvement, improve WHO FC and delay disease progression, including to reduce the risk of death and hospitalisation for PAH.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 4 recommendations for eligibility to PRIME: 1 was accepted and 3 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Dovprela - pretomanid – Orphan - EMEA/H/C/005167/II/0013

Mylan IRE Healthcare Limited

Rapporteur: Filip Josephson

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to update frequency information of several adverse drug reactions (ADRs) as well as to update clinical efficacy information based on final results from study ZeNix (NC007) listed as a specific obligation (SOB/001) in the Annex II. This is a Phase III Partially-Blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid plus Bedaquiline and Pretomanid in Participants with Pulmonary Infection of Either Extensively DrugResistant Tuberculosis (XDRTB), pre-XDR-TB or Treatment Intolerant or NonResponsive Multi-Drug Resistant Tuberculosis (MDRTB)- ZeNix study. The Annex II and Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the list of local representatives in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to SmPC wording.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.2. Gazyvaro - obinutuzumab - Orphan - EMEA/H/C/002799/II/0052

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ulla Wändel Liminga

"Extension of indication to include the pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab for Gazyvaro, based on results from study NP30179; this is a a multicenter, open-label, Phase I/II study evaluating the safety, efficacy, tolerability and pharmacokinetics of escalating doses of glofitamab as a single agent and in combination with obinutuzumab administered after a fixed, single dose pre-treatment of

Gazyvaro in patients with relapsed/refractory B-cell NHL. As a consequence, sections 4.1, 4.2, 4.4, 5.1, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version."

Scope: Withdrawal of Type-II variation application

Action: For information

Request for Supplementary Information adopted on 30.03.2023.

The CHMP noted the withdrawal of the Type-II variation application.

9.1.3. Invirase – saquinavir – EMEA/H/C/000113

Roche Registration GmbH; treatment of HIV-1 infection

Rapporteur: Daniela Philadelphy, Co-Rapporteur: Filip Josephson

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of the marketing authorisation.

9.1.4. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

Orexigen Therapeutics Ireland Limited

Scope: "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly."

Opinion on the request for re-examination

Action: For adoption

Opinion adopted on 30.03.2023. Request for Supplementary Information adopted on 26.01.2023, 15.09.2022, 24.03.2022.

See 2.2

The CHMP agreed that an oral explanation was not needed at this time.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the variation to the terms of the marketing authorisation.

The CHMP assessment report was adopted.

9.1.5. Ninlaro - ixazomib -Orphan - EMEA/H/C/003844/R/0043

Takeda Pharma A/S

Rapporteur: Armando Genazzani, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: Renewal of conditional marketing authorisation

Action: For adoption

Positive Opinion adopted by consensus together with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

9.1.6. Nuceiva - botulinum toxin type a - EMEA/H/C/004587/II/0029

Evolus Pharma B.V.

Rapporteur: Finbarr Leacy

Scope: quality variation

Action: For adoption

Request for Supplementary Information adopted on 30.03.2023.

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.7. Paxlovid - nirmatrelvir / ritonavir - EMEA/H/C/005973/II/0042

Pfizer Europe MA EEIG

Rapporteur: Jean-Michel Race

Scope: "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy, safety and pharmacokinetic information, based on updated results from studies C4671005 (EPIC-HR), C4671002 (EPIC-SR) and C4671006 (EPIC-PEP) as well as a supplemental report to Pop PK analysis PMAR-EQDD-C467a-DP4-1323, following the re-analysis of data after the removal of data related to four sites from the Paxlovid data analysis."

Action: For adoption

Request for Supplementary Information adopted on 25.05.2023.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Synapse Labs Pvt. Ltd. – various – EMEA/H/A-31/1529

Various

Referral Rapporteur: Maria Concepcion Prieto Yerro, Referral Co-Rapporteur: Janet Koenig

Scope: Start of procedure, appointment of rapporteurs, list of questions, timetable

Action: For adoption

Article 31 procedure triggered by the Agency of Medicines and Medical Devices (AEMPS) in Spain, concerning the contract research organisation (CRO) Synapse Labs Pvt. Ltd., located in Kharadi, Pune, India

The CHMP appointed Maria Concepcion Prieto Yerro as referral rapporteur and Janet Koenig as referral Co-Rapporteur. The Co-Rapporteur team will be supported by the Slovakian and the Portuguese NCA.

The CHMP adopted a list of questions with a procedural timetable.

Notifications: 27 June 2023

Start of the procedure (CHMP): July, 2023 CHMP

List of questions: 20 July 2023

Submission of responses: 15 September 2023

Re-start of the procedure: 16 October 2023

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 24 November 2023

Comments: 01 December 2023

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 07 December 2023

CHMP opinion: December, 2023 CHMP

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

July 2023 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Vote by proxy

Elita Poplavska gave a proxy to Outi Mäki-Ikola. Ilko Getov gave a proxy to Bruno Sepodes. Simona Badoi gave a proxy to Carla Torre. Alar Irs gave a proxy to Kristina Dunder. All proxies were valid for the whole meeting.

14.1.2. CHMP membership

No items

14.1.3. CHMP meetings

Alternating face-to-face and virtual meetings

Action: For information

The CHMP noticed the planned meeting schedule for 2024.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for July 2023

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

Agenda of the July 2023 PDCO plenary meeting

Action: For information

The CHMP noted the PDCO agenda.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sean Barry/Francesca Luciani

Reports from BWP July 2023 meeting to CHMP for adoption:

- 13 reports on products in scientific advice and protocol assistance
- 14 reports on products in pre-authorisation procedures
- 4 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Election of Biologics Working Party (BWP) chairperson

Following the call for nominations launched in June, CHMP to elect the chair from the candidates who submitted nominations.

Nomination(s) received

Action: For election

The CHMP elected Sean Barry (SE) as BWP chair.

14.3.3. Election of Quality Working Party (QWP) chairperson

Following the call for nominations launched in June, CHMP to elect the chair from the candidates who submitted nominations.

Nomination(s) received

Action: For election

The CHMP elected Blanka Hirschlerova (CZ) as QWP chair.

14.3.4. Election of Biosimilar Medicinal Product Working Party (BMWP) chairperson

Following the call for nominations launched in June, CHMP to elect the chair from the candidates who submitted nominations.

Nomination(s) received

Action: For election

The CHMP elected Rene Anour (AT) as BMWP chair.

14.3.5. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 26-27 June 2023.

Action: For adoption

The CHMP adopted the NRG table of decisions.

14.3.6. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 03-06 July 2023. Table of Decisions. Listing of SAWP cases for adoption.

Action: For information

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

The CHMP noted the update.

14.3.7. Methodology Working Party (MWP)

Methodology Working Party and Big Data Steering Group joint guideline on Data Quality Frameworks

Action: For discussion

The CHMP noted the MWP and Big Data Steering Group joint guideline on Data Quality Frameworks. The adoption is postponed to the September PROM.

14.4. Cooperation within the EU regulatory network

14.4.1. Update on the new pharma legislation

Action: For information

The CHMP noted the update.

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Product Information for upcoming Comirnaty variant vaccine

Product Information for upcoming Comirnaty variant vaccine for preliminary discussion

Action: For discussion

The CHMP discussed the product information.

15.1.2. Workshop on Acute respiratory distress syndrome (ARDS)

Action: For endorsement

The CHMP ensorsed the workshop.

15.1.3. Q&A on Nitrosamines

Update Q.21 and Q.22

Action: For endorsement

The CHMP endorsed the Q&A on nitrosamines.

15.1.4. 2023 APEC GRM CoE Workshop Agenda, 6 September 2023 in Taiwan

Action: For information

The CHMP noted the agenda for the workshop and endorsed Aaron Sosa Mejia to participate as representative of EMA.

Lists of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 17-20 July 2023 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Daniela Philadelphy	Member	Austria	No interests declared	
Christian Gartner	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Tomas Radimersky	Member	Czechia	No interests declared	
Petr Vrbata	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No interests declared	
Aaron Sosa Mejia	Alternate	Denmark	No participation in final deliberations and voting on:	Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/X/0016
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Beata Maria Jakline Ullrich	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Finbarr Leacy	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Vilma Petrikaite	Member	Lithuania	No interests declared	
Larisa Gorobets	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
Alexandra Branchu	Alternate	Luxembourg	No restrictions applicable to this meeting	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Frantisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No restrictions applicable to this meeting	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Carolina Prieto Fernandez	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Bruno Delafont	Co-opted member	France	No participation in discussion, final deliberations and voting on:	Beyfortus - nirsevimab - EMEA/H/C/005304/II/0005 Imfinzi - durvalumab - EMEA/H/C/004771/II/0057
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Vincent Gazin	Expert	France	No interests declared	
Fabien Carré	Expert	France	No interests declared	
Brenda Holingue	Expert	France	No interests declared	
Umberto Casalegno	Expert	France		
Kairi Rooma	Expert	Estonia	No interests declared	
Tihana Slezak	Expert	Croatia	No interests declared	
Veronica Krogstad	Expert	Norway	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ole Henrik Myrdal	Expert	Norway	No interests declared	
Anne Figenschou Soleng	Expert	Norway	No interests declared	
Heidi Mestl	Expert	Norway	No interests declared	
Ivana Povrazníková	Expert	Slovakia	No interests declared	
Daiana Vasilcanu	Expert	Sweden	No interests declared	
Charlotte Anderberg	Expert	Sweden	No interests declared	
Jenny-Maria Jönsson	Expert	Sweden	No participation in final deliberations and voting on:	Tecentriq - atezolizumab - EMEA/H/C/004143/X/0076 Jemperli - dostarlimab - EMEA/H/C/005204/II/0023 Opdivo - nivolumab - EMEA/H/C/003985/II/0130
Janne Komi	Expert	Finland	No restrictions applicable to this meeting	
Susanne Urach	Expert	Austria	No interests declared	
Bojana Divkovic	Expert	Austria	No interests declared	
Elisabeth Wischnitzki	Expert	Austria	No interests declared	
Lisa Nika	Expert	Austria	No restrictions applicable to this meeting	
Florian Koban	Expert	Austria	No interests declared	
Ieva Rutkovska	Expert	Latvia	No interests declared	
Brigitte Schwarzer-Daum	Expert	Austria	No interests declared	
Elina Rönnemaa	Expert	Sweden	No interests declared	
Andre Elferink	Expert	Netherlands	No interests declared	
Elmer Schabel	Expert	Germany	No interests declared	
Anja Schiel	Expert	Norway	No interests declared	
Niamh Curran	Expert	Ireland	No interests declared	
Iftekhar Khan	Expert	Ireland	No interests declared	
Lars Krueger	Expert	Germany	No restrictions applicable to this meeting	
Poleta Luga	Expert	Germany	No interests declared	
Sara Tognarelli	Expert	Germany	No restrictions applicable to this meeting	
Julia Katharina Maier	Expert	Germany	No interests declared	
Susanne Mueller-Egert	Expert	Germany	No interests declared	
Nancy Postma	Expert	Netherlands	No interests declared	
Hinke Johanna Van der Woude	Expert	Netherlands	No interests declared	
Johanna de Groot	Expert	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Paul Knoop	Expert	Netherlands	No restrictions applicable to this meeting	
Sanne ten Dam	Expert	Netherlands	No interests declared	
Jorn Mulder	Expert	Netherlands	No interests declared	
Laura Rodwell	Expert	Netherlands	No interests declared	
Alida Spruijt	Expert	Netherlands	No interests declared	
Monique van Raamsdonk	Expert	Netherlands	No interests declared	
Hester Peltenburg	Expert	Netherlands	No interests declared	
Elisabeth Johanne Rook	Expert	Netherlands	No interests declared	
Siona Slob	Expert	Netherlands	No interests declared	
Nynke Brouwer	Expert	Netherlands	No interests declared	
Johannes Petrus Theodorus Span	Expert	Netherlands	No interests declared	
Nienke Rodenhuis	Expert	Netherlands	No interests declared	
Sabine van der Putten - de Brouwer	Expert	Netherlands	No restrictions applicable to this meeting	
Ebru Karakoc Madsen	Expert	Denmark	No interests declared	
Thadeus Bao Quan Nguyen	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Kinga Nowicka-Matus	Expert	Denmark	No interests declared	
Emilie Birch Kristensen	Expert	Denmark	No restrictions applicable to this meeting	
Boje Kvorning Pires Ehmsen	Expert	Denmark	No interests declared	
Tina Soon Engraff	Expert	Denmark	No interests declared	
Louisa Braun Exner	Expert	Denmark	No interests declared	
Claus Bang Pedersen	Expert	Denmark	No restrictions applicable to this meeting	
Nicolas Beix	Expert	France	No interests declared	
Celine Jumeau	Expert	France	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Luca Santi	Expert	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert	Italy	No restrictions applicable to this meeting	
Antonella Isgrò	Expert	Italy	No interests declared	
Angelo Molinaro	Expert	Italy	No interests declared	
Milica Mitrevski	Expert	Italy	No interests declared	
Cristina Migali	Expert	Italy	No interests declared	
Angela Garau	Expert	Italy	No interests declared	
Valentina Conti	Expert	Italy	No interests declared	
Valerie Lescrainier	Expert	Belgium	No interests declared	
Olga Kholmanskikh	Expert	Belgium	No interests declared	
Violette Dirix	Expert	Belgium	No interests declared	
Julian Paesler	Expert	Germany	No interests declared	
Marion Haberkamp	Expert	Germany	No interests declared	
George Aislaitner	Expert	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Marta Lafuente Gonzalez	Expert	Spain	No interests declared	
Macarena Gajardo Alvarez	Expert	Spain	No interests declared	
Beatriz Gutiérrez Eugenio	Expert	Spain	No interests declared	
Eva Cantarero	Expert	Spain	No interests declared	
Ana Moreno Oliver	Expert	Spain	No interests declared	
Laura Gómez	Expert	Spain	No interests declared	
Maria del Mar Fuentes González	Expert	Spain	No restrictions applicable to this meeting	
Maria Eugenia Abad Abad	Expert	Spain	No interests declared	
Larissa Higgins	Expert	Ireland	No interests declared	
Priscilla Schoondermark	Expert	Netherlands	No interests declared	
Karolina Kwiatek	Expert	Netherlands	No interests declared	
Therese Klamer	Expert	Netherlands	No participation in discussion, final deliberations and voting on:	Dovprela - pretomanid – Orphan - EMEA/H/C/005167/II/0013
Sabine Mayrhofer	Expert	Germany	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	
Patrick Vrijlandt	Expert	Netherlands	No interests declared	
Peter Mol	Expert	Netherlands	No interests declared	
Maria Victoria Tudanca Pacios	Expert	Spain	No restrictions applicable to this meeting	
Zsofia Gyulai	Expert	Hungary	No interests declared	
Joao Rocha	Expert	Portugal	No restrictions applicable to this meeting	
Rene Anour	Expert	Austria	No interests declared	
Sean Barry	Expert	Ireland	No restrictions applicable to this meeting	
Deepak Rai	Expert	TGA Australia	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with the help of EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

Open (various sections)

Procedure evaluated under the OPEN framework which provides for near-concurrent review by one or more non-EU regulatory authorities, each conducting their own assessment in parallel to the EMA evaluation while sharing scientific expertise and maintaining their scientific and regulatory independence. OPEN aims at facilitating sharing of expertise to tackle common challenges, aligning regulatory approaches between international authorities, speeding up patient access to innovative

medicines and enhancing transparency on regulatory decisions

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

06 October 2023
EMA/CHMP/331325/2023

Annex to 17-20 July 2023 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for July 2023: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for July 2023: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Chenodeoxycholic acid Leadiant - chenodeoxycholic acid - EMEA/H/C/004061/S/0022, Orphan Leadiant GmbH, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
DECTOVA - zanamivir - EMEA/H/C/004102/S/0016 GlaxoSmithKline Trading Services Limited, Rapporteur: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
Elaprase - idursulfase - EMEA/H/C/000700/S/0111 Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
Firdapse - amifampridine - EMEA/H/C/001032/S/0075 SERB SA, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.
Tecovirimat SIGA - tecovirimat - EMEA/H/C/005248/S/0004	Request for supplementary information adopted with a specific timetable.

SIGA Technologies Netherlands B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 20.07.2023, 25.05.2023.	

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Apealea - paclitaxel - EMEA/H/C/004154/R/0017 Inceptua AB, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Inês Ribeiro-Vaz Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Besremi - ropeginterferon alfa-2b - EMEA/H/C/004128/R/0031 AOP Orphan Pharmaceuticals GmbH, Rapporteur: Janet Koenig, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Inês Ribeiro-Vaz	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Bevespi Aerosphere - glycopyrronium / formoterol fumarate dihydrate - EMEA/H/C/004245/R/0017 AstraZeneca AB, Rapporteur: Kristina Dunder, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Jan Neuhauser	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Emgality - galcanezumab - EMEA/H/C/004648/R/0023 Eli Lilly Nederland B.V., Rapporteur: Armando Genazzani, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Erleada - apalutamide - EMEA/H/C/004452/R/0030 Janssen-Cilag International N.V., Rapporteur: Carolina Prieto Fernandez, Co-Rapporteur: Elita	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available

Poplavska, PRAC Rapporteur: Tiphaine Vaillant	information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/R/0038 Recordati Ireland Ltd, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Maria del Pilar Rayon Request for Supplementary Information adopted on 22.06.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Fulphila - pegfilgrastim - EMEA/H/C/004915/R/0042 Viatris Limited, Rapporteur: Martina Weise, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Silodosin Recordati - silodosin - EMEA/H/C/004964/R/0012 Recordati Ireland Ltd, Generic, Generic of Urorec, Rapporteur: Margareta Bego, PRAC Rapporteur: Valentina Di Giovanni Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/R/0083 Biogen Netherlands B.V., Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Martin Huber	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Vantobra - tobramycin - EMEA/H/C/005086/R/0009 PARI Pharma GmbH, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Xofigo - radium-223 - EMEA/H/C/002653/R/0049 Bayer AG, Rapporteur: Janet Koenig, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Rugile Pilviniene Request for Supplementary Information adopted	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can

on 25.05.2023.	be granted with unlimited validity.

B.2.3. Renewals of Conditional Marketing Authorisations

GAVRETO - pralsetinib - EMEA/H/C/005413/R/0014 Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
NINLARO - ixazomib - EMEA/H/C/003844/R/0043, Orphan Takeda Pharma A/S, Rapporteur: Armando Genazzani, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. See 9.1
RYBREVANT - amivantamab - EMEA/H/C/005454/R/0007 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Spevigo - spesolimab - EMEA/H/C/005874/R/0005 Boehringer Ingelheim International GmbH, Rapporteur: Kristina Dunder, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Nathalie Gault	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection PRAC recommendations on signals adopted at the PRAC meeting held on 03-06 July 2023 PRAC:	
Signal of hepatocellular damage and hepatitis	The CHMP adopted the PRAC recommendation.

Lynparza (CAP) – Olaparib Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli PRAC recommendation on a variation **Action:** For adoption	
PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its July 2023 meeting:	
EMEA/H/C/PSUSA/00010020/202211 (aflibercept (ophthalmological indication(s))) CAPS: **Eylea** (EMEA/H/C/002392) (aflibercept), Bayer AG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nathalie Gault, "30/11/2019 To: 30/11/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change(s): Update of section 4.6 of the SmPC (and the patient leaflet, accordingly) to modify the current wording regarding breast-feeding. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010897/202212 (elasomeran (Spikevax), elasomeran / imelasomeran (Spikevax bivalent Original/Omicron BA.1), elasomeran / davesomeran (Spikevax bivalent Original/Omicron BA.4-5)) CAPS: **Spikevax** (EMEA/H/C/005791) (covid-19 mRNA vaccine (nucleoside-modified)), Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "19/06/2022 To: 17/12/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above-mentioned medicinal product, concerning the following changes: Update of sections 4.4 and 4.8 of the SmPC to amend a warning regarding myocarditis and pericarditis. The package leaflet is updated accordingly. Update of section 4.4 of the SmPC to amend a warning regarding use in immunocompromised subjects. Update of section 4.8 of the SmPC to add the adverse reaction mechanical urticaria with a frequency 'Unknown'. The package leaflet is updated accordingly. A revised RMP version 7.0 has been approved. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

EMEA/H/C/PSUSA/00010898/202212 (tozinameran (COMIRNATY), tozinameran/riltozinameran (COMIRNATY Original/Omicron BA.1), tozinameran/famtozinameran (COMIRNATY Original/Omicron BA.4-5)) CAPS: **COMIRNATY** (EMEA/H/C/005735) (covid-19 mRNA vaccine (nucleoside-modified)), BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, "17/06/2022 To: 17/12/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change: Update of section 4.4 of the SmPC to amend the warning/precaution regarding myocarditis and pericarditis and section 2 of the package leaflet accordingly.
EMEA/H/C/PSUSA/00010912/202212 (COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria)) CAPS: **Vaxzevria** (EMEA/H/C/005675) (covid 19 vaccine (chadox1 s [recombinant])), AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "29/06/2022 To: 28/12/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction Venous Thromboembolism with a frequency 'not known'. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010958/202212 (artesunate) CAPS: **Artesunate Amivas** (EMEA/H/C/005550) (artesunate), Amivas Ireland Ltd, Rapporteur: Jayne Crowe, PRAC Rapporteur: Martin Huber, "22/06/2022 To: 22/12/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction immune haemolytic anaemia with a frequency "not known" and an amendment of the warning/precaution regarding PADH as well as update of section 4.8 of the SmPC to add the adverse reaction Electrocardiogram QT prolonged with a frequency "not known". The package leaflet is updated accordingly.

EMEA/H/C/PSUSA/00011014/202212 (efgartigimod alfa) CAPS: **Vyvgart** (EMEA/H/C/005849) (efgartigimod alfa), Argenx, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald, "16/06/2022 To: 16/12/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.2, 4.4, 4.8 and 6.6 of the SmPC to add detail of risk minimisation measures to manage infusion and hypersensitivity-related reactions, to add a warning on the adverse reaction anaphylactic reaction and to add anaphylactic reaction as ADR with a frequency of not known. The package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00011015/202212 (tezepelumab) CAPS: **TEZSPIRE** (EMEA/H/C/005588) (Tezepelumab), AstraZeneca AB, Rapporteur: Finbarr Leacy, PRAC Rapporteur: Eva Jirsová, "17/06/2022 To: 16/12/2022"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation for the above-mentioned medicinal product, concerning the following changes: Update of section 4.8 of the SmPC to add the adverse reaction 'hypersensitivity (including anaphylactic reaction)' with a frequency Not known. The package leaflet is updated accordingly.

B.4. EPARs / WPARs

AQUIPTA - atogepant - EMEA/H/C/005871 AbbVie Deutschland GmbH & Co. KG, Prophylaxis of migraine in adults who have at least 4 migraine days per month., New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Jesduvroq - daprodustat - EMEA/H/C/005746 Glaxosmithkline Trading Services Limited, treatment of anaemia associated with chronic kidney disease (CKD) in adults, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Advate - octocog alfa - EMEA/H/C/000520/II/0119/G Takeda Manufacturing Austria AG, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 26.04.2023.	Positive Opinion adopted by consensus on 20.07.2023.
ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0036/G Baxalta Innovations GmbH, Rapporteur: Daniela Philadelphy Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Aflunov - prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) - EMEA/H/C/002094/II/0084/G Seqirus S.r.l, Rapporteur: Maria Grazia Evandri Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 22.06.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Alymsys - bevacizumab - EMEA/H/C/005286/II/0022 Mabxience Research SL, Rapporteur: Christian Gartner Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.
Cetrotide - cetrorelix - EMEA/H/C/000233/II/0090 Merck Europe B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.
Cosentyx - secukinumab - EMEA/H/C/003729/II/0101 Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
CRYSVITA - Burosumab - EMEA/H/C/004275/II/0035/G, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Kristina	Request for supplementary information adopted with a specific timetable.

Dunder, PRAC Rapporteur: Gabriele Maurer Request for Supplementary Information adopted on 06.07.2023.	
Erleada - apalutamide - EMEA/H/C/004452/II/0032/G Janssen-Cilag International N.V., Rapporteur: Carolina Prieto Fernandez Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/II/0020/G Novo Nordisk A/S, Rapporteur: Daniela Philadelphy Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
Eylea - aflibercept - EMEA/H/C/002392/II/0087 Bayer AG, Rapporteur: Jean-Michel Race Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0045 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0037 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
Fluenz Tetra - influenza vaccine (live attenuated, nasal) - EMEA/H/C/002617/II/0132 AstraZeneca AB, Rapporteur: Christophe Focke Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
Herceptin - trastuzumab - EMEA/H/C/000278/II/0189 Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0064, Orphan CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.

Ivabradine Accord - ivabradine - EMEA/H/C/004241/II/0016/G Accord Healthcare S.L.U., Generic, Generic of Procoralan, Rapporteur: Anastasia Mountaki Request for Supplementary Information adopted on 29.06.2023, 08.12.2022.	Request for supplementary information adopted with a specific timetable.
Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0069/G Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
KANJINTI - trastuzumab - EMEA/H/C/004361/II/0023 Amgen Europe B.V., BREDA, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 06.07.2023.	Request for supplementary information adopted with a specific timetable.
Kevzara - sarilumab - EMEA/H/C/004254/II/0036/G Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 26.04.2023.	Positive Opinion adopted by consensus on 20.07.2023.
LEDAGA - chlormethine - EMEA/H/C/002826/II/0035/G, Orphan Helsinn Birex Pharmaceuticals Limited, Rapporteur: Aaron Sosa Mejia Request for Supplementary Information adopted on 06.07.2023.	Request for supplementary information adopted with a specific timetable.
Metalyse - tenecteplase - EMEA/H/C/000306/II/0069/G Boehringer Ingelheim International GmbH, Rapporteur: Martina Weise Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
Mosquirix - plasmodium falciparum and hepatitis b vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0069 GlaxoSmithkline Biologicals SA, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Mounjaro - tirzepatide -	Request for supplementary information adopted

EMEA/H/C/005620/II/0004/G Eli Lilly Nederland B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted on 29.06.2023, 20.04.2023.	with a specific timetable.
Mounjaro - tirzepatide - EMEA/H/C/005620/II/0006/G Eli Lilly Nederland B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted on 13.07.2023, 12.05.2023.	Request for supplementary information adopted with a specific timetable.
Mounjaro - tirzepatide - EMEA/H/C/005620/II/0008 Eli Lilly Nederland B.V., Rapporteur: Martina Weise Opinion adopted on 29.06.2023.	Positive Opinion adopted by consensus on 29.06.2023.
Nimenrix - meningococcal group a, c, w135 and y conjugate vaccine - EMEA/H/C/002226/II/0126/G Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
Nuceiva - botulinum toxin type a - EMEA/H/C/004587/II/0029 Evolus Pharma B.V., Rapporteur: Finbarr Leacy Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.	Request for supplementary information adopted with a specific timetable. See 9.1
Ogluo - glucagon - EMEA/H/C/005391/II/0011 Tetris Pharma B.V., Rapporteur: Karin Janssen van Doorn Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Oyavas - bevacizumab - EMEA/H/C/005556/II/0022 STADA Arzneimittel AG, Duplicate, Duplicate of Alymsys, Rapporteur: Christian Gartner Request for Supplementary Information adopted on 06.07.2023.	Request for supplementary information adopted with a specific timetable.
Pluvicto - lutetium (177Lu) vipivotide tetraxetan - EMEA/H/C/005483/II/0003 Novartis Europharm Limited, Rapporteur: Janet Koenig Opinion adopted on 13.07.2023. Request for Supplementary Information adopted on 01.06.2023.	Positive Opinion adopted by consensus on 13.07.2023.
Polivy - polatuzumab vedotin -	Positive Opinion adopted by consensus on

EMEA/H/C/004870/II/0021/G, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 04.05.2023.	20.07.2023.
Praluent - alirocumab - EMEA/H/C/003882/II/0081 Sanofi Winthrop Industrie, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
Ranivisio - ranibizumab - EMEA/H/C/005019/II/0005 Midas Pharma GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.
Ranivisio - ranibizumab - EMEA/H/C/005019/II/0006 Midas Pharma GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.
Respreeza - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0066/G CSL Behring GmbH, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
Rybelsus - Semaglutide - EMEA/H/C/004953/II/0033/G Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Supemtek - influenza quadrivalent vaccine (rdna) - EMEA/H/C/005159/II/0011/G Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 08.06.2023, 09.02.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Vaxchora - cholera vaccine, oral, live - EMEA/H/C/003876/II/0020 Emergent Netherlands B.V., Rapporteur: Ingrid Wang Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 20.07.2023.	
VidPrevtyn Beta - SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754/II/0003 Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 20.07.2023, 01.06.2023.	Request for supplementary information adopted with a specific timetable.
Vocabria - cabotegravir - EMEA/H/C/004976/II/0016/G ViiV Healthcare B.V., Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.
Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0041 Merck Sharp & Dohme B.V., Rapporteur: Ingrid Wang Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
Zolsketil pegylated liposomal - doxorubicin - EMEA/H/C/005320/II/0004 Accord Healthcare S.L.U., Rapporteur: Carolina Prieto Fernandez Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
WS2419/G **Herceptin-EMEA/H/C/000278/WS2419/0188/G** **Kadcyla-EMEA/H/C/002389/WS2419/0068/G** Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
WS2471/G **Mosquirix-EMEA/H/W/002300/WS2471/0070/G** **Shingrix-EMEA/H/C/004336/WS2471/0066/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
WS2507 **Bondronat-EMEA/H/C/000101/WS2507/0092** **Bonviva-EMEA/H/C/000501/WS2507/0076**	Request for supplementary information adopted with a specific timetable.

Atnahs Pharma Netherlands B.V., Lead Rapporteur: Thalia Marie Estrup Blicher Request for Supplementary Information adopted on 06.07.2023.	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0035 Baxalta Innovations GmbH, Rapporteur: Daniela Philadelphy, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on anaphylactic reaction and to add 'anaphylactic reaction' to the list of adverse drug reactions (ADRs) with frequency 'Not Known', based on the cumulative review of MAH global database and literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information." Opinion adopted on 13.07.2023. Request for Supplementary Information adopted on 14.04.2023.	Positive Opinion adopted by consensus on 13.07.2023.
Artesunate Amivas - artesunate - EMEA/H/C/005550/II/0004, Orphan Amivas Ireland Ltd, Rapporteur: Jayne Crowe, "Update of sections 4.6 and 5.3 of the SmPC in order to update non-clinical information based on study 362163, which studies cytogenetic damage in rats, and study 9001907, which studies fertility and embryonic development in female rats, listed as a category 3 study in the RMP. In addition, the MAH took the opportunity to introduce minor changes to the PI." Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0051, Orphan Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of section 4.8 of the SmPC in order to update immunogenicity information to remove reference to antibody testing based on an analysis of all completed clinical studies and post-marketing data." Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.
Cerdelga - eliglustat - EMEA/H/C/003724/II/0032, Orphan Sanofi B.V., Rapporteur: Johann Lodewijk	Positive Opinion adopted by consensus on 29.06.2023.

Hillege, "Update of section 4.8 of the SmPC in order to add cough to the list of adverse drug reactions (ADRs) with frequency Common based on the cumulative review of clinical trial data, the MAH global pharmacovigilance database and literature search. The Package Leaflet is updated accordingly." Opinion adopted on 29.06.2023.	
Cometriq - cabozantinib - EMEA/H/C/002640/II/0053, Orphan Ipsen Pharma, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add embolism arterial to the list of adverse drug reactions (ADRs) with frequency Uncommon based on literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
Dovprela - pretomanid - EMEA/H/C/005167/II/0013, Orphan Mylan IRE Healthcare Limited, Rapporteur: Filip Josephson, "Update of sections 4.8 and 5.1 of the SmPC in order to update frequency information of several adverse drug reactions (ADRs) as well as to update clinical efficacy information based on final results from study ZeNix (NC007) listed as a specific obligation (SOB/001) in the Annex II. This is a Phase III Partially-Blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid plus Bedaquiline and Pretomanid in Participants with Pulmonary Infection of Either Extensively DrugResistant Tuberculosis (XDRTB), pre-XDR-TB or Treatment Intolerant or NonResponsive Multi-Drug Resistant Tuberculosis (MDRTB)-ZeNix study. The Annex II and Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.	Request for supplementary information adopted with a specific timetable. See 9.1
Enbrel - etanercept - EMEA/H/C/000262/II/0249 Pfizer Europe MA EEIG, Rapporteur: Maria	Positive Opinion adopted by consensus on 06.07.2023.

Concepcion Prieto Yerro, "Update of section 4.6 of the SmPC in order to update information on breast feeding exposure based on the cumulative review of etanercept specific pharmacology, safety database and published medical literature. The Package Leaflet is updated accordingly. In addition, the MAH is taking this opportunity to correct minor administrative and typographical changes to the SmPC, Labelling and Package Leaflet. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 14.04.2023, 12.01.2023.	
Fasenra - benralizumab - EMEA/H/C/004433/II/0047 AstraZeneca AB, Rapporteur: Fátima Ventura, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric population information based on final results from study D3250C00025; this is an Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children with Severe Eosinophilic Asthma." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus on 20.07.2023.
GAVRETO - pralsetinib - EMEA/H/C/005413/II/0013 Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, "Update of sections 4.4, 4.6 and 5.3 of the SmPC in order to update information on fertility based on final results from study 00571044 (21-0310); this is a 9-week fertility and toxicokinetic study of pralsetinib administered via oral gavage in male Sprague Dawley rats. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce a minor change to the PI and update the list of local representatives in the Package Leaflet." Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
HEPLISAV B - hepatitis b surface antigen (rdna) - EMEA/H/C/005063/II/0026 Dynavax GmbH, Rapporteur: Filip Josephson,	Request for supplementary information adopted with a specific timetable.

"Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to add a 4-dose regimen posology for patients with renal insufficiency including those undergoing haemodialysis and to update safety and pharmacodynamic information based on final results from study HBV-24 "An Open-label, Single Arm Study, Evaluating the Immunogenicity and Safety of HEPLISAV-B in Adults With End-Stage Renal Disease Undergoing Hemodialysis". The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make some editorial updates to the PI mainly to align the wording with the QRD guidance and templates." Request for Supplementary Information adopted on 20.07.2023.	
Imnovid - pomalidomide - EMEA/H/C/002682/II/0050, Orphan Bristol-Myers Squibb Pharma EEIG, Rapporteur: Carolina Prieto Fernandez, "Update of section 5.1 of the SmPC in order to update efficacy and safety information following the assessment of II/0031/G based on OS results from study CC-4047-MM-007 listed as PAES in the Annex II; this is to further investigate the efficacy of pomalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 30.03.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Instanyl - fentanyl - EMEA/H/C/000959/II/0077 Takeda Pharma A/S, Rapporteur: Alexandre Moreau, "Update of section 4.8 of the SmPC in order to add hypersensitivity, anaphylactic reaction and anaphylactic shock to the list of adverse drug reactions (ADRs) with frequency not known based on a cumulative review on safety databases, clinical trials data, fentanyl labels and scientific literature. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0136 Merck Sharp & Dohme B.V., Rapporteur:	Request for supplementary information adopted with a specific timetable.

Armando Genazzani, "Update of section 5.1 of the SmPC in order to provide the final OS data (including analyses/KM plots from favourable prognosis subgroups) following the assessment of procedure II/0104, based on results from study E7080-G000-307/KEYNOTE 581 (REC); A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)." Request for Supplementary Information adopted on 13.07.2023, 25.05.2023.	
Kisplyx - lenvatinib - EMEA/H/C/004224/II/0055 Eisai GmbH, Rapporteur: Karin Janssen van Doorn, "Update of section 5.1 of the SmPC in order to update efficacy information in first-line treatment of patients with renal cell carcinoma (in combination with pembrolizumab), based on the OS final analysis for the overall population from study E7080-G000-307/KEYNOTE 581; this is a multicenter, randomized, open-label, phase 3 study comparing the efficacy and safety of lenvatinib in combination with either pembrolizumab or everolimus versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma (RCC)." Request for Supplementary Information adopted on 13.07.2023, 25.05.2023.	Request for supplementary information adopted with a specific timetable.
Kisqali - ribociclib - EMEA/H/C/004213/II/0040 Novartis Europharm Limited, Rapporteur: Filip Josephson, "Update of section 5.3 of the SmPC in order to update non-clinical safety data information on carcinogenicity based on final results from the following non-clinical studies: DIS R1470078, DIS R0870393, DIS R1470078b and DIS R1370292." Opinion adopted on 29.06.2023.	Positive Opinion adopted by consensus on 29.06.2023.
LUMYKRAS - sotorasib - EMEA/H/C/005522/II/0011 Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 4.5 of the SmPC in order to update information regarding the co-administration of sotorasib with acid reducing agents, based on the results from study 20220024; this is a phase 1, single-	Request for supplementary information adopted with a specific timetable.

center, open-label drug-drug interaction study to evaluate the impact of omeprazole, a proton pump inhibitor, on the pharmacokinetics of sotorasib co-administered with an acidic beverage in healthy volunteers. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 20.07.2023.	
Lupkynis - voclosporin - EMEA/H/C/005256/II/0005 Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Kristina Dunder, "Update of sections 4.5 and 5.2 of the SmPC in order to update pharmacokinetic and safety information based on final results from study AUR-VCS-2021-02, safety data from Phase 2 and 3 studies submitted as part of the initial marketing authorisation application and post-marketing data. AUR-VCS-2021-02 is a single-center, open-label, Phase 1 study to investigate the effect of voclosporin on the pharmacokinetics of simvastatin and simvastatin acid in healthy male and female subjects aged 18 to 55 years." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023, 16.03.2023.	Positive Opinion adopted by consensus on 20.07.2023.
MVABEA - ebola vaccine (rdna, replication-incompetent) - EMEA/H/C/005343/II/0018/G Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, "Grouped application comprising three type II variations as follows: - Update of sections 4.8 and 5.1 of the SmPC in order to add vomiting to the list of adverse drug reactions (ADRs) in children with frequency common and to add immunogenicity data from study VAC52150EBL2004 (PREVAC), listed as a study 3 in the agreed PIP. This was a randomised, double-blind, placebo-controlled, parallel-group Phase 2 study conducted at multiple sites in West Africa to investigate the immunogenicity and safety of 3 Ebola vaccine regimens versus placebo in adults (aged ≥18 years), adolescents (aged 12-17 years), and children (2 age strata: 5-11 years and 1-4 years) who never received a candidate Ebola	Positive Opinion adopted by consensus on 20.07.2023.

vaccine (self-report) and had no history of Ebola virus disease (self-report). - Update of sections 4.2, 4.8 and 5.1 of the SmPC to add interim safety and immunogenicity data from study VAC52150EBL2005, a study conducted by the MAH in infants 4-11 months of age. - Update of section 5.1 of the SmPC to add final immunogenicity data from study VAC52150EBL2011, a study in which an Ad26.ZEBOV booster dose was evaluated in children 1 to 11 years of age (at the time of first vaccination in EBL3001). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes and update the contact details of the local representatives in the Package Leaflet." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023, 30.03.2023.	
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0050, Orphan Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Karin Janssen van Doorn, "Submission of the final report from study SHP634-401 (BALANCE). This is a phase 3b-4, randomized, double-blind, placebo controlled, adaptive study to evaluate symptom improvement and metabolic control among adult subjects with symptomatic hypoparathyroidism treated with recombinant human parathyroid hormone [rhPTH(1-84)]." Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Norvir - ritonavir - EMEA/H/C/000127/II/0169 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3 and 4.5 of the SmPC in order to remove information regarding the DDI with piroxicam based on a review of clinical studies, post-marketing data and literature. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 06.07.2023.	Request for supplementary information adopted with a specific timetable.
NUVAXOVID - covid-19 vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0045 Novavax CZ, a.s., Rapporteur: Johann Lodewijk	Request for supplementary information adopted with a specific timetable.

Hillege, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a new posology regimen - adolescent boosting vaccination based on interim results from study 2019nCOV-301(IR) listed as a category 3 study in the RMP; this is a Phase 3, randomised, observer-blinded, placebo- controlled study to evaluate the efficacy, safety, and immunogenicity of SARS CoV-2 rS with Matrix-M adjuvant in adult participants ≥ 18 years of age with a paediatric expansion (12 to < 18 years of age). The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.	
Olumiant - baricitinib - EMEA/H/C/004085/II/0038 Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC to update efficacy information following the CHMP assessment of procedure R/0025 based on final results from study I4V-MC-JADY (JADY; RA BEYOND); This is a long-term extension study: a Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 20.04.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Paxlovid - nirmatrelvir / ritonavir - EMEA/H/C/005973/II/0042 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy, safety and pharmacokinetic information, based on updated results from studies C4671005 (EPIC-HR), C4671002 (EPIC-SR) and C4671006 (EPIC-PEP) as well as a supplemental report to Pop PK analysis PMAR-EQDD-C467a-DP4-1323, following the reanalysis of data after the removal of data related to four sites from the Paxlovid data analysis." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus on 20.07.2023. See 9.1
Reyataz - atazanavir - EMEA/H/C/000494/II/0137 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.3 and	Positive Opinion adopted by consensus on 20.07.2023.

4.5 in order to add drug-drug interaction information with antiplatelet therapies classified as P2Y12 platelet inhibitors (ticagrelor, clopidogrel and prasugrel), dexamethasone or other corticosteroids, antineoplastics encorafenib or ivosidenib, gonadotropin-releasing hormone (GnRH) receptor antagonist elagolix, kinase inhibitor fostamatinib and antineoplastic apalutamide based on the cumulative review of literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0038 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Update of sections 4.4 and 5.1 of the SmPC in order to include results from a sub-study of Study M14-465. The objective of the sub-study was to assess the immunogenicity of the adjuvanted recombinant glycoprotein E herpes zoster vaccine in rheumatoid arthritis subjects receiving upadacitinib 15 mg once daily (QD) with background MTX. In addition, the MAH is taking this opportunity to correct translation errors in section 4.4 of the Dutch, Finnish, French, German, Hungarian, Italian, Latvian, Lithuanian, Norwegian, Polish, Portuguese, Romanian, Slovakian, Slovenian and Spanish product information." Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Saphnelo - anifrolumab - EMEA/H/C/004975/II/0007 AstraZeneca AB, Rapporteur: Outi Mäki-Ikola, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC based on final results from study D3461C00009 listed as an additional pharmacovigilance activity in the RMP; this is a multicentre, randomised, double-blind, placebo-controlled Phase III extension study to characterise the long-term safety and tolerability of anifrolumab in adult subjects with active systemic lupus erythematosus. In addition, the MAH took the opportunity to implement minor changes to sections 4.2 and	Request for supplementary information adopted with a specific timetable.

6.6 of the SmPC and to the Package Leaflet." Request for Supplementary Information adopted on 20.07.2023, 14.04.2023.	
Saxenda - liraglutide - EMEA/H/C/003780/II/0036 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add 'rash' to the list of adverse drug reactions (ADRs) with frequency common; the Package Leaflet is updated accordingly." Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0065 GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information with COVID-19 mRNA-1273 booster vaccine, based on final results from study ZOSTER-091; this is a phase 3, randomized, open-label, controlled, multi-center clinical study to evaluate the immune response and safety of both herpes zoster subunit vaccine (HZ/su or Shingrix) in healthy adults aged 50 years and older, and the quadrivalent seasonal influenza vaccine (Flu D-QIV or Fluarix Quadrivalent) in healthy adults aged 18 years and older, when administered sequentially or co-administered with mRNA-1273 booster vaccination. In addition, the MAH took the opportunity to introduce a minor change to the PI." Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
Skyrizi - risankizumab - EMEA/H/C/004759/II/0035 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Finbarr Leacy, "Update of sections 4.8 and 5.1 of the SmPC based on final results from study M15-997; this is a Phase 3, single-arm, multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis. In addition, the MAH took the opportunity to implement editorial changes to the SmPC." Request for Supplementary Information adopted on 29.06.2023.	Request for supplementary information adopted with a specific timetable.

Spravato - esketamine - EMEA/H/C/004535/II/0018 Janssen-Cilag International N.V., Rapporteur: Martina Weise, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on the final results from study 54135419TRD3013 (ESCAPE). This is A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing a Selective Serotonin Reuptake Inhibitor/ Serotonin-Norepinephrine Reuptake Inhibitor. In addition, the MAH took the opportunity to introduce minor editorial changes, to update Annex IV and to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
TAVNEOS - avacopan - EMEA/H/C/005523/II/0007, Orphan Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to correct a recently identified calculation error that occurred in the conversion of various non-prednisolone glucocorticoids to their prednisolone-equivalent doses in the pivotal Phase 3 study CL010_168 (ADVOCATE). Furthermore, minor revisions were made to section 4.4 (deletion of the term "viral" from the warning on live viral vaccines to have also not viral vaccines within the scope of the warning), and revised white blood cell count units (L instead of µL))." Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
TEZSPIRE - Tezepelumab - EMEA/H/C/005588/II/0008 AstraZeneca AB, Rapporteur: Finbarr Leacy, "Update of section 4.5 of the SmPC in order to include information relating to the humoral antibody responses induced by the seasonal influenza virus based on final results from study VECTOR (D5180C00031); this is a multicenter, randomized, double-blind, parallel group,	Positive Opinion adopted by consensus on 20.07.2023.

placebo-controlled, phase IIIb study to evaluate the potential effect of tezepelumab on the humoral immune response to seasonal quadrivalent influenza vaccination in adolescent and young adult participants with moderate to severe asthma. In addition, the MAH took the opportunity to implement editorial changes to section 5.1 of the SmPC." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	
Tivicay - dolutegravir - EMEA/H/C/002753/II/0089 ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Update of section 5.2 of the SmPC in order to update Tmax data for the dolutegravir tablet formulations." Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Toviaz - fesoterodine - EMEA/H/C/000723/II/0068 Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.8 of the SmPC in order to add hypoaesthesia to the list of adverse drug reactions (ADRs) with frequency Uncommon based on a cumulative review of safety database cases and literature. The Package Leaflet is updated accordingly. In addition, the MAH would like to take this opportunity to make minor linguistic corrections in line with the QRD template v10.3." Request for Supplementary Information adopted on 13.07.2023.	Request for supplementary information adopted with a specific timetable.
TUKYSA - tucatinib - EMEA/H/C/005263/II/0013 Seagen B.V., Rapporteur: Aaron Sosa Mejia, "Update of section 5.1 of the SmPC to reflect updated efficacy results from study ONT-380-206 (HER2CLIMB), listed as a PAES in the Annex II of the Product Information. This is a phase 2 randomized, double-blinded, controlled study of tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast carcinoma. The Annex II is updated accordingly." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 22.06.2023.	Positive Opinion adopted by consensus on 20.07.2023.

Ultomiris - ravulizumab - EMEA/H/C/004954/II/0034 Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study ALXN1210-PNH-302, a Phase III, randomised, open-label, active controlled study of ALXN1210 versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) currently treated with eculizumab, listed as a category 3 study in the RMP. The Package Leaflet is updated accordingly." Opinion adopted on 13.07.2023. Request for Supplementary Information adopted on 16.03.2023.	Positive Opinion adopted by consensus on 13.07.2023.
Vaxzevria - covid 19 vaccine (chadox1 s [recombinant]) - EMEA/H/C/005675/II/0090 AstraZeneca AB, Rapporteur: Sol Ruiz, "Submission of the final report from study D8111R00007 (RAVEN) listed as a category 3 study in the RMP. This is an observational retrospective cohort study using secondary databases to establish effectiveness of Vaxzevria in England." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Victoza - liraglutide - EMEA/H/C/001026/II/0066 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add Dysgeusia to the list of adverse drug reactions (ADRs) with frequency Uncommon based on the cumulative review of scientific literature. The Package Leaflet is updated accordingly." Opinion adopted on 13.07.2023. Request for Supplementary Information adopted on 12.05.2023.	Positive Opinion adopted by consensus on 13.07.2023.
Vipdomet - alogliptin / metformin - EMEA/H/C/002654/II/0044 Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Vitamin B12 decrease or deficiency and to update the list of adverse drug reactions (ADRs) in accordance with the recent update of the PI	Request for supplementary information adopted with a specific timetable.

for Glucophage, which is the reference label for the compound metformin, and following the request by MHRA on 20 June 2022 for all products containing metformin." Request for Supplementary Information adopted on 06.07.2023.	
VITRAKVI - larotrectinib - EMEA/H/C/004919/II/0030 Bayer AG, Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to update the efficacy data and the list of adverse drug reactions (ADRs) based on interim results from studies 20289 and 20290. In addition, the MAH revised the posology recommendations in patients with liver function abnormalities and amended an existing warning on hepatotoxicity, updated information on drug-drug interaction regarding the effects of CYP3A inhibitors and inducers and P-gp inducers. The Package Leaflet is updated accordingly." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Vyndaqel - tafamidis - EMEA/H/C/002294/II/0087, Orphan Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC in order to remove the adverse reaction 'vaginal infection' based on a search of cumulative post-marketing cases. The Package Leaflet and Annex IV are updated accordingly. In addition, the MAH takes the opportunity to update the company logo on the Package Leaflet." Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
ZABDENO - ebola vaccine (rdna, replication-incompetent) - EMEA/H/C/005337/II/0015/G Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, "Grouped application comprising three type II variations as follows: - Update of sections 4.8 and 5.1 of the SmPC in order to add crying and hyperhidrosis to the list of adverse drug reactions (ADRs) in children with frequency very common and common, respectively and to add immunogenicity data from study VAC52150EBL2004 (PREVAC), listed as a study 3 in the agreed PIP. This was a	Positive Opinion adopted by consensus on 20.07.2023.

randomised, double-blind, placebo-controlled, parallel-group Phase 2 study conducted at multiple sites in West Africa to investigate the immunogenicity and safety of 3 Ebola vaccine regimens versus placebo in adults (aged ≥18 years), adolescents (aged 12-17 years), and children (2 age strata: 5-11 years and 1-4 years) who never received a candidate Ebola vaccine (self-report) and had no history of Ebola virus disease (self-report). - Update of sections 4.2, 4.8 and 5.1 of the SmPC to add interim safety and immunogenicity data from study VAC52150EBL2005, a study conducted by the MAH in infants 4-11 months of age. - Update of sections 4.8 and 5.1 of the SmPC to add final safety and immunogenicity data from study VAC52150EBL2011, a study in which an Ad26.ZEBOV booster dose was evaluated in children 1 to 11 years of age (at the time of first vaccination in EBL3001). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes and update the contact details of the local representatives in the Package Leaflet." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023, 30.03.2023.	
WS2450/G **Glyxambi-** **EMEA/H/C/003833/WS2450/0051/G** **Synjardy-** **EMEA/H/C/003770/WS2450/0070/G** Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "C.I.4: Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to modify administration instructions to the elderly, amend an existing warning for the elderly and remove the warning for 'Cardiac Failure' in order to align with the Jardiance Product Information; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.z: Update of section 4.4 of the SmPC in order to introduce a rewording related to use in patients with type 1 diabetes in order to align with the Jardiance Product Information; the Package Leaflet is updated accordingly."	Positive Opinion adopted by consensus on 20.07.2023.

Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 26.04.2023.	
WS2481 **TOBI Podhaler-** **EMEA/H/C/002155/WS2481/0058** Viatris Healthcare Limited, Lead Rapporteur: Johann Lodewijk Hillege, "Update of section 4.4 of the SmPC in order to amend an existing warning on ototoxicity based on literature review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes." Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
WS2485 **Incruse Ellipta-** **EMEA/H/C/002809/WS2485/0037** **Rolufta Ellipta-** **EMEA/H/C/004654/WS2485/0021** GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.2, 4.6 and 4.8 of the SmPC in order to add 'Dysphonia' and 'Oropharyngeal pain' to the list of adverse drug reactions (ADRs) with frequency rare, and to update the wording regarding the administration instructions and for pregnancy and breast-feeding. The Package Leaflet and Labelling are also updated. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
WS2489/G **Kinzalmono-** **EMEA/H/C/000211/WS2489/0119/G** **Micardis-** **EMEA/H/C/000209/WS2489/0127/G** **Pritor-** **EMEA/H/C/000210/WS2489/0132/G** Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, "Grouped application consisting of: C.I.4: Update of section 4.8 of the SmPC in order to include "hyponatremia" to the list of adverse drug reactions (ADRs) with frequency "rare", based on post-marketing data and	Request for supplementary information adopted with a specific timetable.

literature; C.I.z (Type IB unforeseen): Update of section 4.2 to include the possibility of using the combination of telmisartan and amlodipine for lowering blood pressure of the SmPC based on literature; C.I.z (Type IB unforeseen): Update of section 4.7 of the SmPC to replace the terms "dizziness" and "drowsiness" by "syncope" and "vertigo" to align with adverse reactions table in section 4.8 of SmPC. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet; bring the PI in line with the latest QRD template version 10.3; and to implement editorial changes to the SmPC." Request for Supplementary Information adopted on 20.07.2023, 15.06.2023.	

B.5.3. CHMP-PRAC assessed procedures

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0016 Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, "Submission of an updated RMP version 4 in order to update post-approval commitments. In addition, the MAH took the opportunity to update Annex II of the SmPC to expand the B4741015 PAES study protocol to sites in Europe and Israel for Apexxnar. B4741015 is a Phase 4 study using a test negative design to evaluate the effectiveness of Apexxnar against vaccine type radiologically confirmed community acquired pneumonia in adults ≥ 65 years of age." Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
Dovato - dolutegravir / lamivudine - EMEA/H/C/004909/II/0040/G ViiV Healthcare B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: David Olsen, "Submission of the final reports from study 204861 (GEMINI-1) and study 205543 (GEMINI-2) listed as category 3 studies in the RMP; these are phase 3, randomised, double-blind, multicentre, parallel group, non-inferiority studies evaluating the efficacy, safety and	Positive Opinion adopted by consensus on 20.07.2023.

tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults. The RMP version 4.1 has also been submitted." Opinion adopted on 20.07.2023.	
Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0031 Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Inês Ribeiro-Vaz, "Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update safety, efficacy and pharmacokinetic information based on data from study DS8201-A-U301 and study DS8201-A-U302. Study U301 was a Phase 3, randomized, 2-arm, open-label, multicenter study designed to compare the safety and efficacy of T-DXd vs TPC in HER2-positive, unresectable and/or metastatic BC subjects who were resistant or refractory to T-DM1. Study U301 was listed as a specific obligation in the Annex II. Study U302 was a Phase 3, multicenter, randomized, open-label, 2-arm, active-controlled study in subjects with unresectable and/or metastatic HER2-positive (IHC 3+ or ISH-positive) BC previously treated with trastuzumab plus taxane in the advanced/metastatic setting or who had progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab plus taxane. The Package Leaflet and Annex II are updated accordingly. The RMP has also been updated (version 6.0)." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 08.06.2023.	Positive Opinion adopted by consensus on 06.07.2023.
EVUSHELD - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0009/G AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, "Grouped application comprising two type II variations (REC 23) as follows: C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study TACKLE (D8851C00001). C.I.4 - Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on final results from	Request for supplementary information adopted with a specific timetable.

studies PROVENT (D8850C00002) and STORM CHASER (D8850C00003). The RMP version 4.1 has also been submitted." Request for Supplementary Information adopted on 20.07.2023.	
Fintepla - fenfluramine - EMEA/H/C/003933/II/0015, Orphan UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "To update sections 4.2 and 5.2 of the SmPC to update the safety information based on final results from study ZX008-1903 listed as a category 3 study in the RMP; this is a Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZX008 (Fenfluramine Hydrochloride) in Subjects with Varying Degrees of Hepatic Impairment. The primary objective of this study was to compare the PK of a single dose of ZX008 (fenfluramine HCl) in subjects with varying degrees of hepatic impairment with that of healthy matched control subjects. The updated RMP version 2.15 has also been submitted." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023, 30.03.2023, 12.01.2023, 29.09.2022.	Positive Opinion adopted by consensus on 20.07.2023.
LUMYKRAS - sotorasib - EMEA/H/C/005522/II/0007 Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Update of sections 4.2 and 5.2 of the SmPC in order to update recommendations for patients with moderate to severe hepatic impairment following final results from study 20200362 listed as a category 3 PASS study in the EU RMP; this is a Phase I clinical study to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in subjects with moderate or severe hepatic impairment compared with subjects who have normal hepatic function. The EU RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3." Request for Supplementary Information adopted on 06.07.2023, 16.03.2023.	Request for supplementary information adopted with a specific timetable.

Lynparza - olaparib - EMEA/H/C/003726/II/0061 AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, "Update of sections 4.8 and 5.1 of the SmPC in order to update the overall survival and safety information following procedure H/C/003726/II/0048, based on the final results from study D081SC00001 (PROpel), listed as a PAES in the Annex II; this is a randomised, double-blind, placebo-controlled, multicentre phase III study of olaparib plus abiraterone relative to placebo plus abiraterone as first-line therapy in men with metastatic castration resistant prostate cancer; The RMP version 27 has also been submitted." Request for Supplementary Information adopted on 06.07.2023.	Request for supplementary information adopted with a specific timetable.
Mayzent - siponimod - EMEA/H/C/004712/II/0020 Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Maria del Pilar Rayon, "Update of sections 4.4 and 4.8 of the SmPC in order to add "Progressive multifocal leukoencephalopathy (PML)" to the list of adverse drug reactions (ADRs) with frequency "not know" based on post-marketing data. The Annex II (Physician's Checklist), and Package Leaflet are updated accordingly. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the text regarding herpes viral infection in the Package Leaflet in alignment with the currently approved SmPC." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 14.04.2023.	Positive Opinion adopted by consensus on 06.07.2023.
Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056 Orexigen Therapeutics Ireland Limited, "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP	Re-examination Negative Opinion adopted by consensus on 20.07.2023. See 9.1

version 13 are updated accordingly." Opinion adopted on 20.07.2023, 30.03.2023. Request for Supplementary Information adopted on 26.01.2023, 15.09.2022, 24.03.2022.	
Paxlovid - nirmatrelvir / ritonavir - EMEA/H/C/005973/II/0043/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "Grouped application comprising two type II variations as follows: - Update of section 5.1 of the SmPC in order to include new virology updates. - Update of sections 4.5 and 5.2 of the SmPC in order to update interaction information related to CYP2B6, MATE1 and OCT1. The RMP version 3.0 has also been submitted and updated." Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Prolia - denosumab - EMEA/H/C/001120/II/0098 Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, "Update of sections 4.2, 4.4, 5.1 and 5.2 in order to update efficacy, pharmacokinetic and safety information for paediatric population following the assessment of P46/043 and P46/044 based on final results from study 20130173, listed as a category 3 study in the RMP and study 20170534. Study 20130173 was a prospective, multicenter, open-label, single-arm phase 3 study to evaluate the safety, efficacy, and PK of denosumab in children 2 to 17 years of age with OI. Study 20170534 was an open-label, prospective, extension study of study 20130173. The RMP version 31 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 12.05.2023.	Positive Opinion adopted by consensus on 06.07.2023.
Rekovelle - follitropin delta - EMEA/H/C/003994/II/0037/G Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst, "Grouped application comprising two type II variations as follows:	Positive Opinion adopted by consensus on 20.07.2023.

- Update of sections 4.1, 4.2, 4.4, 4.5 and 5.1 of the SmPC to update the safety information following final results from study 000304 (BEYOND). This is a randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol and a GnRH antagonist protocol in women undergoing controlled ovarian stimulation. - Update of section 4.8 of the SmPC, including the tabulation of adverse drug reactions based on pooled safety data from studies ESTHER-1, ESTHER-2, 000273, 000145, BEYOND and RAINBOW. The updated RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 26.04.2023.	
Simponi - golimumab - EMEA/H/C/000992/II/0113 Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, "Submission of the final report from study CNTO148UCO1001 (PURSUIT PEDS PK) listed as a category 3 study in the RMP. This is a phase 1b open-label study to assess the safety and pharmacokinetics of subcutaneously administered golimumab, a human anti-TNFα antibody, in paediatric subjects with moderately to severely active ulcerative colitis. The RMP version 26.1 has also been submitted." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 12.05.2023.	Positive Opinion adopted by consensus on 06.07.2023.
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0078 Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Inês Ribeiro-Vaz, "Update of section 5.1 of the SmPC in order to include the final overall survival (OS) analysis results based on final results from study WO30070 listed as a PAES in the Annex II to fulfil ANX/PAE 003; this is a Phase III, multicenter, randomized, placebo-controlled	Request for supplementary information adopted with a specific timetable.

study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma. The RMP version 27 has also been submitted. In addition, the MAH took the opportunity to update Annex II of the SmPC." Request for Supplementary Information adopted on 06.07.2023.	
Tecvayli - teclistamab - EMEA/H/C/005865/II/0006 Janssen-Cilag International N.V., Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Jana Lukacisinova, "Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update the posology recommendations to include the possibility of bi-weekly dosing, based on interim results from study 64007957MMY1001 (MajesTEC-1); this is a phase 1/2, single-arm, open-label, multicenter study of teclistamab administered as monotherapy to adult subjects with relapsed or refractory multiple myeloma. The Package Leaflet is updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3 and update the list of local representatives in the Package Leaflet." Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Tysabri - natalizumab - EMEA/H/C/000603/II/0136 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, "Update of sections 4.2 and 4.4 of the SmPC to modify administration instructions and update educational guidance to enable the subcutaneous formulation to be administered outside a clinical setting by healthcare professionals based on the cumulative review of post-marketing and clinical study data. The Package Leaflet and Annex IID are updated accordingly. The RMP version 29.1 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes." Request for Supplementary Information adopted on 20.07.2023.	Request for supplementary information adopted with a specific timetable.
Vaxzevria - covid 19 vaccine (chadox1 s [recombinant]) -	Positive Opinion adopted by consensus on

EMEA/H/C/005675/II/0089 AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 4.8 of the SmPC in order to update the frequencies of 'dizziness' and 'abdominal pain' in the list of adverse drug reactions (ADRs) to common and the frequency of 'fever' to very common based on final results and final pooled analysis for studies COV001, COV002, COV003 and COV005. Update of section 5.1 of the SmPC in order to update safety and efficacy information, based on final results and final pooled analysis for studies COV001, COV002, COV003 and COV005 as well as the final manuscript for COV004, listed as category 3 studies in the RMP. Study COV001 is phase I/II, single-blind, randomised, active-controlled, multicenter study in healthy adults aged 18-55 years; Study COV002 is a phase II/III, single-blind, randomised, active-controlled, multicenter study in adults ≥ 18 years of age and at high risk of exposure to COVID-19; Study COV003 is a phase III, single-blind, randomised, controlled, multicenter study in adults ≥ 18 years of age at high risk of exposure to SARS-CoV-2; Study COV005 is a phase I/II, double-blind, randomised, placebo-controlled, multicenter study in adults 18 to 65 years of age with or without HIV. Study COV004 is a phase IB/II single-blind, randomized controlled trial of the (AZD1222) vaccine in adults in Kenya. The Package Leaflet is updated accordingly. The RMP version 7.0 has also been submitted." Opinion adopted on 20.07.2023. Request for Supplementary Information adopted on 25.05.2023.	20.07.2023.
Vyvgart - efgartigimod alfa - EMEA/H/C/005849/II/0006, Orphan Argenx, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald, "Update of sections 4.4 and 4.5 of the SmPC in order to amend an existing warning on use of vaccination and update drug-drug interaction information on vaccines based on final results from study ARGX-113-2102; this is a phase 1, randomized, open-label, placebo-controlled, parallel-group study to evaluate the immune response to PNEUMOVAX 23 in healthy participants receiving efgartigimod IV 10 mg/kg	Request for supplementary information adopted with a specific timetable.

or placebo. The RMP version 1.2 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 06.07.2023.	
WS2438/G **Relvar Ellipta-** **EMEA/H/C/002673/WS2438/0061/G** **Revinty Ellipta-** **EMEA/H/C/002745/WS2438/0058/G** GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Monica Martinez Redondo, "Grouped application consisting of 1) Update sections 4.2 and 5.1 of the SmPC to include results from study HZA107116. This is a randomised, double-blind, parallel group, multicentre, stratified, study evaluating the efficacy and safety of once daily fluticasone furoate/vilanterol inhalation powder compared to once daily fluticasone furoate inhalation powder in the treatment of asthma in participants aged 5 to 17 years old (inclusive) currently uncontrolled on inhaled corticosteroids. The Package Leaflet and Labelling are updated accordingly. The RMP version 12.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC; 2) Submission of final report from Phase 2b study HZA106855 (FF dose ranging) which gives information regarding the dose selection for FF combination in study HZA107116; 3) Submission of final report from Phase 2b study HZA106853 (VI dose ranging) which gives information regarding the dose selection for VI combination in study HZA107116." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 12.05.2023.	Positive Opinion adopted by consensus on 06.07.2023.

B.5.4. PRAC assessed procedures

PRAC Led **Arixtra - fondaparinux sodium -** **EMEA/H/C/000403/II/0087** Mylan Ire Healthcare Limited, PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "To update section 4.8 of the SmPC to	Request for supplementary information adopted with a specific timetable.

update the ADR table following the assessment of PSUSA (EMEA/H/C/PSUSA/00001467/202112). The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 06.07.2023, 14.04.2023.	
PRAC Led **Deltyba - delamanid - EMEA/H/C/002552/II/0061, Orphan** Otsuka Novel Products GmbH, PRAC Rapporteur: Jo Robays, PRAC-CHMP liaison: Christophe Focke, "Update of sections 4.2 and 4.4 of the SmPC in order to update the treatment duration based on final results from EU PASS (protocol no. 242-12-402), listed as a category 3 study in the RMP. This is a "A Multicentre, EU-wide, Non-Interventional Post-Authorisation Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis (MDR-TB) Patients". This treatment registry was for monitoring and documenting Deltyba use in routine medical practice and aimed to assess compliance with the recommendations in the authorised product information when prescribed as part of an appropriate combination regimen (ACR) for the treatment of MDR-TB. The Package Leaflet is updated accordingly. Update of Annex II and the RMP to version 5.0 to remove the additional Risk Minimisation Measures (aRMMs)." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 16.03.2023, 01.12.2022.	Positive Opinion adopted by consensus on 06.07.2023.
PRAC Led **Entyvio - vedolizumab - EMEA/H/C/002782/II/0073** Takeda Pharma A/S, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final report from study MLN0002_401 listed as a category 3 study in the RMP in order to fulfil MEA/001.2; this is an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's disease. The RMP version 8.0 has also been submitted. Update of the SmPC sections 4.2, 4.4, 4.8 and Annex II (removal of additional risk minimisation measures based on	Positive Opinion adopted by consensus on 06.07.2023.

data from this study. The package leaflet has been updated in accordance." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 16.03.2023, 29.09.2022. "	
PRAC Led **Fasenra - benralizumab - EMEA/H/C/004433/II/0049/G** AstraZeneca AB, PRAC Rapporteur: David Olsen, PRAC-CHMP liaison: Ingrid Wang, "Grouped application consisting of: 1) Submission of an updated RMP version 5 in order to remove the safety concern of missing information on use in pregnant and lactating women. Consequently, the MAH proposes to remove study D3250R00026 as an additional pharmacovigilance activity, and to remove the commitment to conduct additional pharmacovigilance for the use of benralizumab in pregnant and lactating women with severe eosinophilic asthma. 2) Submission of an updated RMP version 5 in order to remove the safety concern of important potential risk of serious infections." Request for Supplementary Information adopted on 06.07.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Halaven - Eribulin - EMEA/H/C/002084/II/0067** Eisai GmbH, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Filip Josephson, "Submission of the final report from study IRENE 504 (E7389-M044-504), listed as a category 3 study in the RMP. This was a post-authorisation non-interventional safety study to characterise and determine the incidence of eribulin-induced peripheral neuropathy (PN), and frequency and time to resolution of eribulin-induced PN in adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease treated with eribulin. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. The RMP version 8 has also been submitted." Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.

PRAC Led **Kineret - anakinra - EMEA/H/C/000363/II/0090** Swedish Orphan Biovitrum AB (publ), PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP version 6.2 in order to add DRESS as an important potential risk as well as the removal of the additional risk minimisation measures for serious infections, following the assessment of procedure PSUSA/00000209/202205. Annex II is updated in accordance." Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
PRAC Led **Neulasta - pegfilgrastim - EMEA/H/C/000420/II/0121** Amgen Europe B.V., PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from PASS study 20170701 listed as a category 3 study in the RMP. This is a cross-sectional survey study to assess the effectiveness of the Neulasta Patient Alert Card and to measure medication errors related to the use of the Neulasta On-Body Injector. The RMP version 9.0 was accepted." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 01.12.2022.	Positive Opinion adopted by consensus on 06.07.2023.
PRAC Led **Nexium Control - esomeprazole - EMEA/H/C/002618/II/0038** GlaxoSmithKline Dungarvan Ltd, PRAC Rapporteur: Rugile Pilviniene, PRAC-CHMP liaison: Vilma Petrikaite, "Submission of an updated RMP version 2.0 in order to update the list of safety concerns to meet the definition of important risk and missing information provided in GVP Module V Rev. 2" Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 08.06.2023.	Positive Opinion adopted by consensus on 06.07.2023.
PRAC Led **NutropinAq - somatropin - EMEA/H/C/000315/II/0077** Ipsen Pharma, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an	Positive Opinion adopted by consensus on 06.07.2023.

updated RMP version 4.2 in order to remove the safety concerns in compliance with GVP Module V Revision 2. In addition, the MAH took the opportunity to add data from final clinical study report of International Cooperative Growth Study (iNCGS) registry (non-interventional study) and exposure and safety information and to bring the RMP in line with the format described in GVP V (rev. 2)." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 14.04.2023, 12.01.2023.	
PRAC Led **Parsabiv - etelcalcetide - EMEA/H/C/003995/II/0021** Amgen Europe B.V., PRAC Rapporteur: Valentina Di Giovanni, PRAC-CHMP liaison: Armando Genazzani, "Submission of the final report from study 20170561 listed as a category 3 study in the RMP. This is an observational PASS to evaluate the potential association between Parsabiv and gastrointestinal bleeding." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 16.03.2023.	Positive Opinion adopted by consensus on 06.07.2023.
PRAC Led **Remicade - infliximab - EMEA/H/C/000240/II/0241** Janssen Biologics B.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report for the PSOLAR (C0168Z03) registry "A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics: PSOLAR", listed as a category 3 study in the RMP (MEA114). This is an international, multicenter, prospective observational registry for monitoring the long-term safety experience and clinical status of patients ≥18 years of age who are eligible to receive or are actively receiving any systemic therapies for psoriasis, including those currently receiving or planning to receive infliximab. The RMP version 21.1 has also been submitted." Request for Supplementary Information adopted on 06.07.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led	Request for supplementary information adopted

Replagal - agalsidase alfa - EMEA/H/C/000369/II/0126 Takeda Pharmaceuticals International AG Ireland Branch, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from the Fabry Outcome Survey (FOS) registry study. The FOS (Fabry Outcome Survey) was a prospective, multicenter, observational, open-ended disease registry designed to document the clinical outcome over time of patients with Fabry disease, irrespective of their treatment." Request for Supplementary Information adopted on 06.07.2023.	with a specific timetable.
PRAC Led **Symkevi - tezacaftor / ivacaftor - EMEA/H/C/004682/II/0039, Orphan** Vertex Pharmaceuticals (Ireland) Limited, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final report from PASS study VX17-661-117 listed as a category 3 study in the RMP. This is an Observational Study to Evaluate the Utilization Patterns and Real-World Effects of Tezacaftor and Ivacaftor Combination Therapy (TEZ/IVA) in Patients With Cystic Fibrosis (CF). The RMP version 3.4 has also been submitted." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 16.03.2023.	Positive Opinion adopted by consensus on 06.07.2023.
PRAC Led **VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0061** Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of an updated RMP version 12 in order to remove certain risks from the list of safety concerns." Request for Supplementary Information adopted on 06.07.2023, 14.04.2023, 09.02.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **XOSPATA - gilteritinib - EMEA/H/C/004752/II/0012, Orphan** Astellas Pharma Europe B.V., PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of the final report from study 2215-PV-0001 - Evaluation of the effectiveness of the Xospata Routine Risk Minimisation Measures	Positive Opinion adopted by consensus on 06.07.2023.

(RMMs) and an additional Risk Minimisation Measure (aRMM): A Cross sectional study among Healthcare Professionals to assess awareness and knowledge, listed as a category 3 study in the RMP. The RMP version 3.1 has also been submitted." Opinion adopted on 06.07.2023. Request for Supplementary Information adopted on 16.03.2023.	
PRAC Led **Zavesca - miglustat - EMEA/H/C/000435/II/0076** Janssen-Cilag International N.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP version 15.1 in order to remove risks in line with GVP module V revision 2. The MAH has also taken the opportunity to introduce minor changes, such as update of the post-marketing exposure data and alignment with the latest Company EU-RMP Template." Request for Supplementary Information adopted on 06.07.2023, 16.03.2023.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Zytiga - abiraterone acetate - EMEA/H/C/002321/II/0072** Janssen-Cilag International N.V., Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Carolina Prieto Fernandez, "Submission of an updated RMP version 15.1 in order to align with Good Pharmacovigilance Practices Module V, Revision 2." Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
PRAC Led **WS2491** **Lantus-EMEA/H/C/000284/WS2491/0127** **Toujeo-EMEA/H/C/000309/WS2491/0122** Sanofi-Aventis Deutschland GmbH, Lead PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "C.I.11.z - To update the RMP of Toujeo and Lantus following removal of the "Medication error due to non-compliance with instructions to use a new needle for each injection: wrong dose injected due to blocked needle" from the list of safety concerns (EMEA/H/C/000309/II/0105/G), to: -remove the follow-up questionnaire for the topic "Medication error due to non-compliance	Positive Opinion adopted by consensus on 20.07.2023.

with instructions to use a new needle for each injection: wrong dose injected due to blocked needle" from routine pharmacovigilance activities (Part III); -remove the suspected blockage of needle questionnaire (Annex 4); -update with the revised DLP (Part II)." Opinion adopted on 20.07.2023.	

B.5.5. CHMP-CAT assessed procedures

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0034, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 20.07.2023, 14.07.2023. Request for Supplementary Information adopted on 16.06.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0037/G, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 20.07.2023, 14.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0021, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani Request for Supplementary Information adopted on 14.07.2023.	Request for supplementary information adopted with a specific timetable.
CARVYKTI - ciltacabtagene autoleucel - EMEA/H/C/005095/II/0018, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 14.07.2023.	Request for supplementary information adopted with a specific timetable.
CARVYKTI - ciltacabtagene autoleucel - EMEA/H/C/005095/II/0019, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Opinion adopted on 20.07.2023, 14.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0069, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 20.07.2023, 14.07.2023. Request for Supplementary Information adopted on 15.06.2023, 17.05.2023.	Positive Opinion adopted by consensus on 20.07.2023.
Libmeldy - atidarsagene autotemcel - EMEA/H/C/005321/II/0017, Orphan, ATMP Orchard Therapeutics (Netherlands) B.V., Rapporteur: Johannes Hendrikus Ovelgonne, CHMP Coordinator: Johann Lodewijk Hillege Opinion adopted on 20.07.2023, 14.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.

B.5.6. CHMP-PRAC-CAT assessed procedures

Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0040, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Johannes Hendrikus Ovelgonne, CHMP Coordinator: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.4 and 5.1 of the SmPC in order to add a new warning and precaution capturing the theoretical risk of tumorigenicity as a result of vector integration and to include a new statement indicating random instances of vector integration are possible; based on final results from studies 2220205 and 2220117, and literature. The Package Leaflet is updated accordingly. The RMP version 3 has also been submitted." Request for Supplementary Information adopted on 14.07.2023.	Request for supplementary information adopted with a specific timetable.

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2427/G **Silodosin Recordati- EMEA/H/C/004964/WS2427/0011/G** **Silodyx- EMEA/H/C/001209/WS2427/0051/G** **Urorec- EMEA/H/C/001092/WS2427/0054/G**	Positive Opinion adopted by consensus on 13.07.2023.

Recordati Ireland Ltd, Generic, Generic of Urorec, Lead Rapporteur: Margareta Bego Opinion adopted on 13.07.2023. Request for Supplementary Information adopted on 08.06.2023.	
WS2474 **Nuwiq-EMEA/H/C/002813/WS2474/0054** **Vihuma-EMEA/H/C/004459/WS2474/0036** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
WS2476 **Ambirix-EMEA/H/C/000426/WS2476/0128** **Fendrix-EMEA/H/C/000550/WS2476/0083** **Infanrix hexa-EMEA/H/C/000296/WS2476/0331** **Twinrix Adult-EMEA/H/C/000112/WS2476/0163** **Twinrix Paediatric-EMEA/H/C/000129/WS2476/0164** GlaxoSmithKline Biologicals, Lead Rapporteur: Christophe Focke Opinion adopted on 06.07.2023.	Positive Opinion adopted by consensus on 06.07.2023.
WS2480 **Esperoct-EMEA/H/C/004883/WS2480/0019** **NovoEight-EMEA/H/C/002719/WS2480/0041** **NovoSeven-EMEA/H/C/000074/WS2480/0122** **Refixia-EMEA/H/C/004178/WS2480/0034** Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
WS2482/G **Vfend-EMEA/H/C/000387/WS2482/0150/G** Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 20.07.2023.	Positive Opinion adopted by consensus on 20.07.2023.
WS2490 **HyQvia-EMEA/H/C/002491/WS2490/0090** **Kiovig-EMEA/H/C/000628/WS2490/0122** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus	Positive Opinion adopted by consensus on 13.07.2023.

Opinion adopted on 13.07.2023.	
WS2495 **Hexacima-** **EMEA/H/C/002702/WS2495/0149** **Hexyon-** **EMEA/H/C/002796/WS2495/0153** **MenQuadfi-** **EMEA/H/C/005084/WS2495/0024** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
WS2498/G **EVOTAZ-** **EMEA/H/C/003904/WS2498/0045/G** **Reyataz-** **EMEA/H/C/000494/WS2498/0138/G** Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Bruno Sepodes, Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
WS2499 **Circadin-** **EMEA/H/C/000695/WS2499/0069** **Melatonin Neurim-** **EMEA/H/C/005603/WS2499/0001** RAD Neurim Pharmaceuticals EEC SARL, Lead Rapporteur: Bruno Sepodes Opinion adopted on 29.06.2023.	Positive Opinion adopted by consensus on 29.06.2023.
WS2505/G **Rixathon-** **EMEA/H/C/003903/WS2505/0066/G** **Riximyo-** **EMEA/H/C/004729/WS2505/0067/G** Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, "C.I.2.a - To update section 6.6 of the SmPC of Rixathon and Riximyo (duplicate of Rixathon) to remove the additional paragraph `Aseptic preparation' to be in line with the reference product Mabthera. A6 - To change the ATC Code of rituximab from L01X C02 to L01FA0. Furthermore, the MAH has taken the opportunity to include minor editorial changes in the EN, DA, DE, FR, HR, IS, LV and MT translations." Opinion adopted on 13.07.2023.	Positive Opinion adopted by consensus on 13.07.2023.
WS2510 **Lixiana-EMEA/H/C/002629/WS2510/0047** **Roteas-EMEA/H/C/004339/WS2510/0034**	Positive Opinion adopted by consensus on 13.07.2023.

Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 13.07.2023.

B.5.9. Information on withdrawn type II variation / WS procedure

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

in vitro diagnostic medical device - EMEA/H/D/006340 in vitro diagnostic device for laboratory use, intended for the qualitative detection of BRAF V600 mutations in DNA extracted from formalin-fixed, paraffin-embedded human tissue.
dasiglucagon - EMEA/H/C/006214 treatment of severe hypoglycemia in patients with diabetes
levetiracetam - EMEA/H/C/006186 treatment of partial onset seizures
ustekinumab - EMEA/H/C/006221 treatment of adult patients with moderately to severely active plaque psoriasis, Crohn’s disease and active ulcerative colitis and active psoriatic arthritis
nilotinib - EMEA/H/C/006315 treatment of Philadelphia chromosome positive chronic myelogenous leukaemia (CML)
crovalimab - EMEA/H/C/006061 treatment of paroxysmal nocturnal haemoglobinuria
single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein f stabilized in the prefusion conformation – OPEN - EMEA/H/C/006278 Prevention of lower respiratory tract disease (LRTD) and acute respiratory disease (ARD) caused by respiratory syncytial virus (RSV)
teriparatide - EMEA/H/C/005687 treatment of osteoporosis
in vitro diagnostic medical device -

EMEA/H/D/006308
detection of HER2 antigen

in vitro diagnostic medical device - EMEA/H/D/006310
immunohistochemical assay utilising an anti-PD-L1 monoclonal primary antibody

zolbetuximab - EMEA/H/C/005868, Orphan
Astellas Pharma Europe B.V., treatment of locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

macitentan / tadalafil - EMEA/H/C/005001
treatment of pulmonary arterial hypertension (PAH) in adult
patients

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Abilify Maintena - aripiprazole - EMEA/H/C/002755/X/0045
Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to introduce a new pharmaceutical form associated with two new strengths (720 and 960 mg Prolonged-release suspension for injection).
The RMP (version 12.1) is updated in accordance."

Reagila - cariprazine - EMEA/H/C/002770/X/0033
Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins, "Extension application to introduce a new pharmaceutical form (orodispersible tablets).
The RMP (version 3.0) is updated in accordance."

Spevigo - spesolimab - EMEA/H/C/005874/X/0006/G
Boehringer Ingelheim International GmbH, Rapporteur: Kristina Dunder, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Nathalie Gault, "Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (150 mg) and new route of administration

(subcutaneous use), for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. This line extension is grouped with a type II variation (C.I.6.a) to extend the indication for Spevigo 450 mg concentrate for solution for infusion to include treatment of generalised pustular psoriasis (GPP) flares in adolescents (from 12 years of age), based on final results from study 1368-0027 (Effisayil 2) and extrapolation; this is a multi-center, randomized, parallel group, double blind, placebo controlled, phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (spesolimab) compared to placebo in preventing GPP flares in patients with history of GPP. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce editorial changes to the PI and update the list of local representatives in the Package Leaflet."

TEPADINA - thiotepa - EMEA/H/C/001046/X/0049
ADIENNE S.r.l. S.U., Rapporteur: Alexandre Moreau, "Extension application to add a new strength (200 mg powder and solvent for solution for infusion)."

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

arpraziquantel - EMEA/H/W/004252, Article 58
treatment of schistosomiasis in children
List of Questions adopted on 30.03.2023.

azacitidine - EMEA/H/C/006154
Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML)
List of Questions adopted on 26.04.2023.

exagamglogene autotemcel - EMEA/H/C/005763, Orphan, ATMP
Vertex Pharmaceuticals (Ireland) Limited, treatment of transfusion-dependent β-thalassemia and sickle cell disease

List of Questions adopted on 17.05.2023.

Cufence - trientine - EMEA/H/C/004111/X/0014/G
Univar Solutions BV, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ana Sofia Diniz Martins, "Extension application to add a new strength (100 mg capsule, hard) grouped with a type IA variation (B.II.b.4.b) The RMP (version 1.3) is updated in accordance.
The marketing authorisation holder took the opportunity to align the PI to the latest QRD template (version 10.3)."
List of Questions adopted on 25.05.2023.

Eribulin - EMEA/H/C/006134
treatment of breast cancer and liposarcoma
List of Questions adopted on 23.02.2023.

elranatamab - EMEA/H/C/005908, Orphan
Pfizer Europe MA EEIG, Treatment of adult patients with relapsed or refractory multiple myeloma
List of Questions adopted on 25.05.2023.

germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/006053
indicated for in vitro radiolabelling of specific carrier molecules to be used for positron emission tomography (PET) imaging
List of Questions adopted on 26.04.2023.

ibuprofen - EMEA/H/C/006129
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age
List of Questions adopted on 30.03.2023.

paclitaxel - EMEA/H/C/006173
treatment of metastatic breast cancer
List of Questions adopted on 25.05.2023.

leriglitazone - EMEA/H/C/005757, Orphan
Minoryx Therapeutics S.L., the treatment of cerebral progression and myelopathy in male patients with adrenoleukodystrophy (ALD).
List of Questions adopted on 15.12.2022.

momelotinib - EMEA/H/C/005768, Orphan
Glaxosmithkline Trading Services Limited, treatment of disease-related splenomegaly or symptoms and anaemia
List of Questions adopted on 30.03.2023.

PHEBURANE - sodium phenylbutyrate -

EMEA/H/C/002500/X/0035
Eurocept International B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, "Extension application to introduce a new pharmaceutical form associated with a new strength (350 mg/ml oral solution).
The RMP (version 0.1) is updated in accordance."
List of Questions adopted on 25.05.2023.

tofersen - EMEA/H/C/005493, Orphan
Biogen Netherlands B.V., treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
List of Questions adopted on 30.03.2023.

ranibizumab - EMEA/H/C/006055
treatment of neovascular age-related macular degeneration (AMD)
List of Questions adopted on 23.02.2023.

rozanolixizumab - EMEA/H/C/005824, Orphan
UCB Pharma, Treatment of generalised myasthenia gravis (gMG)
List of Questions adopted on 30.03.2023.

ustekinumab - EMEA/H/C/006101
treatment of plaque psoriasis, arthritis psoriatic, Crohn's Disease and ulcerative colitis
List of Questions adopted on 30.03.2023.

Veltassa - patiromer - EMEA/H/C/004180/X/0031/G
Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, PRAC Rapporteur: Kirsti Villikka, "Extension application to introduce a new strength (1 g powder for oral suspension), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of population from 6 to 18 years old for Veltassa based on final results from paediatric study RLY5016-206P (EMERALD); this is a phase 2, open-label, multiple dose study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer for oral suspension in children and adolescents 2 to less than 18 years of age with chronic kidney disease and hyperkalaemia. As a consequence, sections 1, 2, 4.1, 4.2, 4.8, 4.9, 5.1 and 6.5 of the SmPC are updated. The Package Leaflet and Labelling are

updated in accordance. Version 2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes."
List of Questions adopted on 30.03.2023.

in vitro diagnostic medical device - EMEA/H/D/006232
to detect rearrangements involving the ALK gene via fluorescence
Request for Supplementary Information adopted on 22.06.2023.

Yuflyma - adalimumab - EMEA/H/C/005188/X/0022
Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Mari Thorn, "Extension application to add a new strength (20 mg solution for injection). The indications for the new strength are identical to those already approved for the 40 mg strength. The RMP (version 2.1) has also been submitted. In addition, the MAH took the opportunity to include editorial changes ."
List of Questions adopted on 25.05.2023.

B.6.4. Annual Re-assessments: timetables for adoption

MVABEA - Ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005343/S/0019
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

Qarziba - dinutuximab beta - EMEA/H/C/003918/S/0053, Orphan
EUSA Pharma (Netherlands) B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Gabriele Maurer

ZABDENO - Ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005337/S/0017
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Atazanavir Krka - atazanavir - EMEA/H/C/004859/R/0004

KRKA, d.d., Novo mesto, Generic, Generic of Reyataz, Rapporteur: Tomas Radimersky, PRAC Rapporteur: Nathalie Gault

Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/R/0035

Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Inês Ribeiro-Vaz

Febuxostat Krka - febuxostat - EMEA/H/C/004773/R/0008

KRKA, d.d., Novo mesto, Generic, Generic of Adenuric, Rapporteur: John Joseph Borg, PRAC Rapporteur: Jan Neuhauser

LUMYKRAS - sotorasib - EMEA/H/C/005522/R/0012

Amgen Europe B.V., Rapporteur: Alexandre Moreau, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Ocaliva - obeticholic acid - EMEA/H/C/004093/R/0042, Orphan

Advanz Pharma Limited, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Liana Gross-Martirosyan

Tecartus - brexucabtagene autoleucel - EMEA/H/C/005102/R/0034, Orphan, ATMP

Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Rune Kjeken, CHMP Coordinators: Jan Mueller-Berghaus and Ingrid Wang, PRAC Rapporteur: Menno van der Elst

Vizimpro - dacomitinib - EMEA/H/C/004779/R/0011

Pfizer Europe MA EEIG, Rapporteur: Carolina Prieto Fernandez, Co-Rapporteur: Eva Skovlund, PRAC Rapporteur: Menno van der Elst

Zydelig - idelalisib - EMEA/H/C/003843/R/0058

Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

ADCETRIS - brentuximab vedotin - EMEA/H/C/002455/II/0109, Orphan Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) for ADCETRIS based on the final overall survival results of Echelon-2 (SGN035-014), A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 19.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."	
Bimzelx - bimekizumab - EMEA/H/C/005316/II/0020 UCB Pharma S.A., Rapporteur: Finbarr Leacy, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Liana Gross-Martirosyan, "Extension of indication to include treatment of moderate to severe hidradenitis suppurativa (HS) in adults, based on final results from study HS0003 (BE HEARD I) and study HS0004 (BE HEARD II). These are phase 3, randomized, double blind, placebo controlled, multicenter, pivotal studies evaluating the efficacy and safety of bimekizumab in study participants with moderate to severe HS. Further supportive data are based on the results of phase 2 study HS0001 and phase 3 currently ongoing open-label extension study HS0005. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.10 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD	

template version 10.3."

Onivyde pegylated liposomal - irinotecan hydrochloride trihydrate - EMEA/H/C/004125/II/0034, Orphan
Les Laboratoires Servier, Rapporteur: Filip Josephson, PRAC Rapporteur: David Olsen, "Extension of indication to include first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas for Onivyde in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) based on final results from phase 3 study NAPOLI 3 (D-US-60010-001); this is an interventional study with a primary objective to evaluate the efficacy of the regimen of irinotecan liposome injection + oxaliplatin + 5-fluorouracil (5-FU)/leucovorin (LV) versus nab-paclitaxel + gemcitabine in improving overall survival (OS) in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas; As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. The updated RMP version 4.1 is also submitted."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Accofil - filgrastim - EMEA/H/C/003956/II/0057/G
Accord Healthcare S.L.U., Rapporteur: Outi Mäki-Ikola

Adtralza - tralokinumab - EMEA/H/C/005255/II/0010
LEO Pharma A/S, Rapporteur: Jayne Crowe

Benlysta - belimumab - EMEA/H/C/002015/II/0115/G
GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder

Byooviz - ranibizumab - EMEA/H/C/005545/II/0012/G
Samsung Bioepis NL B.V., Rapporteur: Christian Gartner

Cinacalcet Mylan - cinacalcet - EMEA/H/C/004014/II/0023/G
Mylan Pharmaceuticals Limited, Generic,

Generic of Mimpara, Rapporteur: Tomas Radimersky

COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0183
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

Darunavir Mylan - darunavir - EMEA/H/C/004068/II/0021
Mylan Pharmaceuticals Limited, Generic, Generic of Prezista, Rapporteur: John Joseph Borg

Dukoral - cholera vaccine (inactivated, oral) - EMEA/H/C/000476/II/0071
Valneva Sweden AB, Rapporteur: Kristina Dunder

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004240/II/0025
Mylan Pharmaceuticals Limited, Generic, Generic of Atripla (SRD), Rapporteur: Bruno Sepodes

Entyvio - vedolizumab - EMEA/H/C/002782/II/0079/G
Takeda Pharma A/S, Rapporteur: Armando Genazzani

Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0039
Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

Giapreza - angiotensin II - EMEA/H/C/004930/II/0024
Paion Deutschland GmbH, Rapporteur: Maria Concepcion Prieto Yerro

GONAL-f - follitropin alfa - EMEA/H/C/000071/II/0163/G
Merck Europe B.V., Rapporteur: Johann Lodewijk Hillege

Imraldi - adalimumab - EMEA/H/C/004279/II/0066/G
Samsung Bioepis NL B.V., Rapporteur: Outi Mäki-Ikola

Lenalidomide Mylan - lenalidomide - EMEA/H/C/005306/II/0014

Mylan Ireland Limited, Generic, Generic of Revlimid, Rapporteur: Anastasia Mountaki

Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0032
AstraZeneca AB, Rapporteur: Larisa Gorobets

Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0029/G, Orphan
Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia

Nepexto - etanercept - EMEA/H/C/004711/II/0023
Mylan IRE Healthcare Limited, Rapporteur: Martina Weise

Nepexto - etanercept - EMEA/H/C/004711/II/0024
Mylan IRE Healthcare Limited, Rapporteur: Martina Weise

Opzelura - ruxolitinib - EMEA/H/C/005843/II/0002/G
Incyte Biosciences Distribution B.V., Rapporteur: Johann Lodewijk Hillege

Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0115
Zr Pharma& GmbH, Rapporteur: Filip Josephson

Pergoveris - follitropin alfa / lutropin alfa - EMEA/H/C/000714/II/0087/G
Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher

Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - EMEA/H/C/001104/II/0215/G
Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder

Ranivisio - ranibizumab - EMEA/H/C/005019/II/0008
Midas Pharma GmbH, Rapporteur: Jan Mueller-Berghaus

Remicade - infliximab - EMEA/H/C/000240/II/0242
Janssen Biologics B.V., Rapporteur: Kristina Dunder

Remsima - infliximab - EMEA/H/C/002576/II/0131/G
Celltrion Healthcare Hungary Kft., Rapporteur:

Outi Mäki-Ikola

Respreeza - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0071
CSL Behring GmbH, Rapporteur: Kristina Dunder

Simponi - golimumab - EMEA/H/C/000992/II/0115
Janssen Biologics B.V., Rapporteur: Kristina Dunder

Skyrizi - risankizumab - EMEA/H/C/004759/II/0042
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Finbarr Leacy

Soliris - eculizumab - EMEA/H/C/000791/II/0128/G, Orphan
Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez

Ultomiris - ravulizumab - EMEA/H/C/004954/II/0039
Alexion Europe SAS, Rapporteur: Carolina Prieto Fernandez

Uptravi - selexipag - EMEA/H/C/003774/II/0039
Janssen-Cilag International N.V., Rapporteur: Martina Weise

VEYVONDI - vonicog alfa - EMEA/H/C/004454/II/0031
Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus

Xeljanz - tofacitinib - EMEA/H/C/004214/II/0053/G
Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani

WS2522/G
Dengue Tetravalent Vaccine (Live, Attenuated) Takeda-
EMEA/H/W/005362/WS2522/0007/G
Qdenga-
EMEA/H/C/005155/WS2522/0008/G
Takeda GmbH, Lead Rapporteur: Sol Ruiz

WS2525/G
Hexacima-
EMEA/H/C/002702/WS2525/0151/G
Hexyon-
EMEA/H/C/002796/WS2525/0155/G

MenQuadfi-
EMEA/H/C/005084/WS2525/0025/G
Sanofi Pasteur, Lead Rapporteur: Daniela Philadelphy

WS2542/G
Ongentys-
EMEA/H/C/002790/WS2542/0059/G
Ontilyv-
EMEA/H/C/005782/WS2542/0014/G
Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

BIMERVAX - SARS-CoV-2 virus, variants B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer - EMEA/H/C/006058/II/0002
Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Submission of the final report from study HIPRA-HH-1 listed as a category 3 study in the RMP. This is a phase I/IIa study to evaluate safety and immunogenicity of Recombinant protein RBD fusion dimer candidate vaccine against SARS-COV-2 in adult healthy volunteers."

BIMERVAX - SARS-CoV-2 virus, variants B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer - EMEA/H/C/006058/II/0004
Hipra Human Health S.L., Rapporteur: Beata Maria Jakline Ullrich, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and immunogenicity information after a fourth dose based on interim results from study HIPRA-HH-2 listed as a category 3 study in the RMP; this is a Phase IIb, Double-Blind, Randomised, Active - Controlled, Multicentre, Non-Inferiority Trial Followed By A Phase III, Single-Arm, Open-Label Trial To Assess Immunogenicity And Safety Of A Booster Vaccination With A Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-COV-2 In Adults Fully Vaccinated Against Covid-19 Followed By An Extension Period To Study A Fourth Dose Administration Of PHH-1V. The Package Leaflet is updated accordingly. In addition, the MAH submitted the full user consultation with target patient groups."

BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0053/G, Orphan

Amgen Europe B.V., Rapporteur: Alexandre Moreau, "A grouped application consisting of:
Type II (C.I.4): Update of sections 4.2, 5.1 and 6.6 of the SmPC in order to update the dexamethasone premedication guidance for paediatric patients with relapsed/refractory and high-risk first relapsed ALL, to add dexamethasone premedication information from study MT103-205 and study 20120215, and to add a statement that the administration of Blincyto for BSA of less than 0.4 m2 has not been established. In addition, the MAH took the opportunity to update the name of ATC pharmacological subgroup according to WHO ATC Index and to delete "intravenous catheter" from the important note statement regarding flushing and to introduce minor editorial changes to the PI. The Package Leaflet is updated accordingly.
Type IB (C.I.11.z): Update of the due dates for post-authorisation safety studies 20150136 and 20180130 in the Annex II D in order to align with the RMP version 16.0, following commitment agreed on during procedure EMEA/H/C/003731/IB/0050."

Brilique - ticagrelor - EMEA/H/C/001241/II/0061

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2 and 4.4 of the SmPC in order to include a warning related to Single Antiplatelet Therapy (SAPT) in Patients with Acute Coronary Syndrome (ACS) who have undergone a Percutaneous Coronary Intervention (PCI) procedure and who have an increased risk of bleeding based on literature."

COMIRNATY - covid-19 mrna vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0186/G

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Grouped application consisting of:
C.I.13: Submission of the final report from study WI235284 (Emory) listed as a category 3 study in the RMP. This is a low-interventional study to determine the RSV burden and outcomes in pregnant women and older adults requiring hospitalisation, to determine the

effectiveness of COVID-19 mRNA vaccine when administered outside of the clinical setting as well as to estimate the effectiveness of 2 doses of COVID-19 mRNA vaccine against hospitalisation for acute respiratory illness due to SARS-CoV-2 infection. C.I.13: Submission of the final report from study WI255886 (Bristol) listed as a category 3 study in the RMP. This is a low-interventional Avon Community Acquired Pneumonia Surveillance Study (a pan-pandemic acute lower respiratory tract disease surveillance study) to determine the effectiveness of COVID-19 mRNA vaccine and of the bivalent Omicron-modified vaccine when administered outside of the clinical setting, to estimate the effectiveness of COVID-19 mRNA vaccine against hospitalisation for acute respiratory illness due to SARS-CoV-2 infection and to assess the effectiveness of bivalent Omicron modified vaccines following their introduction in individuals 18 years of age and older."	
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0082 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Submission of the final report from study PCI-32765CAN3001 in order to address the Post Authorisation Measure (MEA017); this is a phase 3b, multicenter, open-label long-term extension study designed to collect long-term safety data."	
INREBIC - fedratinib - EMEA/H/C/005026/II/0017, Orphan Bristol-Myers Squibb Pharma EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.4 and 4.5 of the SmPC in order to update drug-drug interaction information with dual inhibitors of CYP3A4 and CYP2C19, based on final results from study FEDR-CP-004; this is a phase 1, open-label study to evaluate the effect of a dual CYP2C19 and CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fedratinib in healthy adult subjects."	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0139 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of section 5.1 of the SmPC in order to update clinical information, based on results from study	

KEYNOTE-716 listed as a PAES in the Annex II. This is a randomized, double-blind phase 3 study of adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. The Annex II is updated accordingly."

Keytruda - pembrolizumab - EMEA/H/C/003820/II/0141

Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-826; this is a phase 3 randomized, double-blind, placebo-controlled trial of pembrolizumab (MK-3475) plus chemotherapy versus chemotherapy plus placebo for the first-line treatment of persistent, recurrent, or metastatic cervical cancer. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Kyprolis - carfilzomib - EMEA/H/C/003790/II/0058, Orphan

Amgen Europe B.V., Rapporteur: Carolina Prieto Fernandez, "Submission of the final report from study 20160275 (CANDOR). This is a randomized, open-label, Phase 3 study comparing carfilzomib, dexamethasone, and daratumumab to carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma."

Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0033

AstraZeneca AB, Rapporteur: Larisa Gorobets, "Update of section 4.8 of the SmPC to include information on constipation to the summary of safety profile and to add constipation to the list of adverse drug reactions (ADRs) with frequency Common based on literature review and MAH safety database. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce editorial changes to the PI."

Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0080

Teva B.V., Rapporteur: Outi Mäki-Ikola, "Update of section 4.4 of the SmPC in order to add a class-effect warning risk of Acute Myeloid Leukaemia and Myelodysplastic Syndrome in

breast and lung cancer patients in conjunction with chemotherapy and/or radiotherapy based on the cumulative review of literature and MAH safety database. The Package Leaflet is updated accordingly.”	
Lupkynis - voclosporin - EMEA/H/C/005256/II/0010 Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Kristina Dunder, “Submission of the final study report from AUR-VCS-2016-02 (AURORA 2) Kidney Biopsy Substudy, listed as a category 3 study in the RMP. The AURORA 2 extension trial included an optional biopsy substudy which was designed to assess renal histology from tissue samples taken prior to and after approximately 18 months of randomized treatment with voclosporin or placebo.”	
Mayzent - siponimod - EMEA/H/C/004712/II/0023 Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, “Update of section 5.1 of the SmPC in order to present data on the effect of siponimod on delaying the progression to EDSS ≥7 (time-to-wheelchair) based on post-hoc analysis of study CBAF312A2304 (EXPAND).”	
Mounjaro - tirzepatide - EMEA/H/C/005620/II/0010 Eli Lilly Nederland B.V., Rapporteur: Martina Weise, “Update of section 4.8 of the SmPC in order to add ‘anaphylactic reaction’ and ‘angioedema’ to the list of adverse drug reactions (ADRs) with frequency rare, based on reviews of post-marketing safety data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI.”	
Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0030, Orphan Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, “Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy, pharmacokinetic and safety information based on interim results from study WI203680 - MyeChild 01-International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia – Incorporating an Embedded Dose	

Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy. This is a dose finding sub-study aimed to identify the optimum tolerated number of doses of GO 3 mg/m2 (up to a maximum of 3 doses) which can be combined safely with AraC plus mitoxantrone or liposomal DAUNO in induction therapy."

Nexviadyme - avalglucosidase alfa - EMEA/H/C/005501/II/0012

Sanofi B.V., Rapporteur: Christian Gartner, "Submission of the final report from study LTS13769 listed as a category 3 study in the RMP. This is an interventional, open-label, multicenter, multinational extension study to evaluate long-term safety and pharmacokinetics of repeated biweekly infusions of avalglucosidase alfa in patients with Pompe disease."

NUVAXOVID - covid-19 vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0054

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from study 702-111; this is a non-clinical study to assess the immunogenicity and protective efficacy of sub-protective doses of SARSCoV-2 rS with Matrix-M adjuvant in rhesus macaques."

Opzelura - ruxolitinib - EMEA/H/C/005843/II/0003

Incyte Biosciences Distribution B.V., Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to update posology, safety and efficacy information based on final results from study INCB 18424-308; this is a Phase III, double-blind, vehicle-controlled, randomized withdrawal and treatment-extension study to assess the long-term efficacy and safety of ruxolitinib cream in participants with vitiligo (TRuE-V LTE). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."

Qutenza - capsaicin - EMEA/H/C/000909/II/0060

Grunenthal GmbH, Rapporteur: Bruno Sepodes, "Update of sections 4.2 and 5.1 of the SmPC in order to update guidance to healthcare

professionals regarding progressive response with repeated treatments and to include additional information, based on recently published literature and clinical data.”	
Rukobia - fostemsavir - EMEA/H/C/005011/II/0011 ViiV Healthcare B.V., Rapporteur: Janet Koenig, “Update of section 5.1 of the SmPC in order to update cross-resistance information based on results from virology study aimed at further characterisation of HIV-1 gp120 amino acid polymorphism E202.”	
Rybelsus - Semaglutide - EMEA/H/C/004953/II/0036 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.7 and 4.8 of the SmPC in order to add ‘Dizziness’ to the list of adverse drug reactions (ADRs) with frequency common and update instructions for driving and using machines. The Package Leaflet is updated accordingly.”	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0126 MCM Vaccine B.V., Rapporteur: Christophe Focke, “Update of sections 4.2 and 5.1 of the SmPC in order to add information on interchangeable use of Vaxelis with other hexavalent vaccines based on final results from study V419-016. In addition, the MAH took this opportunity to introduce minor editorial changes.”	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0128 MCM Vaccine B.V., Rapporteur: Christophe Focke, “Update of sections 4.5 and 5.1 of the SmPC in order to add drug-drug interaction information with meningococcal B conjugate vaccine and update immunogenicity information for anti-PRP (Hib) following co-administration with meningococcal B vaccine based on final results from study OVG 2018/05 - Immunogenicity and reactogenicity of	

concomitantly administered hexavalent and group B meningococcal vaccines in infancy; this is an open-label, non-inferiority, randomized clinical trial that compared the immune response and assessed the safety of Vaxelis and control vaccine (Infanrix hexa) when co-administered with 4 component meningococcal B vaccine (4CMenB) along with other routine infant vaccines. The Package Leaflet is updated accordingly."

Veltassa - patiromer - EMEA/H/C/004180/II/0034/G

Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Grouped application consisting of three Type II variations (C.I.4):
Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy information based on final results from study PAT-CR-302 (Diamond); this is a Phase 3b international, double-blind, placebo-controlled, randomised withdrawal, parallel-group study of patiromer for the management of hyperkalaemia (HK) in patients receiving renin-angiotensin-aldosterone system inhibitors (RAASi) for the treatment of heart failure (HF). In addition, the MAH took the opportunity to implement editorial changes to the SmPC.
Update of sections 4.8 and 5.1 of the SmPC in order to update safety information based on a pooled safety database. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.
Update of section 4.8 of the SmPC in order to add "Hypersensitivity" to the list of adverse drug reactions (ADRs) with frequency "not known", based on post-marketing data."

Xevudy - sotrovimab - EMEA/H/C/005676/II/0018

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of section 5.1 of the SmPC with data on the in vitro activity of sotrovimab in a pseudotyped virus assay against the Omicron XBB.1.5 and BN.1 spike variants (PC-23-0104), the Omicron CH.1.1 spike variant (PC-23-0108) and the Omicron BR.2 and XBF spike variants (PC-23-0117), as well as data on the in vitro

activity of sotrovimab in a live virus assay against the SARS-CoV-2 XBB.1.5 variant (PC-23-0106) and the CH.1.1 variant (PC-23-0118)."

Xevudy - sotrovimab - EMEA/H/C/005676/II/0019/G

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to update posology recommendations and administration instructions and to update efficacy, pharmacokinetic and safety information, based on results from studies COMET-TAIL (phase 3 study and safety substudy; 217114), COMET-PEAK (216912), Japan-PK (217653) and BLAZE-4, and from a Population PK (PopPK) report. These clinical studies were conducted to assess the efficacy, safety and tolerability of sotrovimab given intramuscularly (IM) versus intravenously (IV) for the treatment of mild/moderate coronavirus disease 2019 (COVID-19) in high-risk, non-hospitalized patients (COMET-TAIL phase 3 study); to assess the safety and tolerability of single ascending dose of sotrovimab (COMET-TAIL safety substudy); to assess safety, tolerability, PK and viral pharmacodynamics (PD) of sotrovimab in participants with early mild-to-moderate COVID-19 (COMET-PEAK); to assess PK, safety and tolerability of IV and IM sotrovimab in healthy Japanese and Caucasian participants (Japan-PK); and to evaluate the impact of monoclonal antibodies such as LY3819253 + sotrovimab on viral clearance and clinical outcomes in participants with COVID-19 illness (BLAZE-4). The Package Leaflet is updated accordingly."

Zejula - niraparib - EMEA/H/C/004249/II/0044, Orphan

GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, "Submission of the modelling report with the results from the population pharmacokinetic and exposure-response modelling exercises (REC 7)."

WS2488
Aluvia-EMEA/H/W/000764/WS2488/0118
Kaletra-EMEA/H/C/000368/WS2488/0197
Norvir-EMEA/H/C/000127/WS2488/0168

AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Johann Lodewijk Hillege, "To update section 4.5 in order to align with the text in the Prezista product information and reflect and additional Drug-Drug Interaction with dabigatran etexilate and edoxaban following the final assessment report for Norvir LEG 033.12. The Package Leaflet is updated accordingly. Furthermore, the MAH has taken the opportunity to implement minor editorial changes to the Romanian and Norwegian Patient Information Leaflets"

WS2509/G
Anoro Ellipta-
EMEA/H/C/002751/WS2509/0042/G
Laventair Ellipta-
EMEA/H/C/003754/WS2509/0045/G
GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Finbarr Leacy, "Grouped application comprising two type II variations (C.I.4) as follows:
- Update of section 4.8 of the SmPC in order to delete 'rash' from the list of adverse drug reactions (ADRs) with frequency uncommon based on the cumulative review of the MAH safety database, clinical trial data and literature.
- To include significant changes to sections 2, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.5 of the SmPC, sections 4, 5, 7 and 11 of the Labelling and sections 2, 3 and 6 of the Package Leaflet for the medicinal products Anoro and Laventair containing the active substances Umeclidinium Bromide and Vilanterol following the assessment of the medicinal products Trelegy and Rolufta Ellipta, which also contain the active substances fluticasone furoate, umeclidinium bromide and vilanterol, via procedure EMEA/H/C/004363/R/0023 and EMEA/H/C/004654/R/0019. The same wording is used for the combination product.
The Package Leaflet and Labelling are updated accordingly. The Annex II is updated. In addition, the MAH took the opportunity to introduce minor editorial changes and to bring the PI in line with the latest QRD template."

WS2520/G
Lyrica-
EMEA/H/C/000546/WS2520/0124/G
Pregabalin Pfizer-

EMEA/H/C/003880/WS2520/0052/G
Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, "Grouped application comprising two type II as follows:
C.I.4 - Update of sections 4.4 and 5.1 of the SmPC in order to add information on potential abuse in recreational drug users based on final results from study A0081365 "A Phase 4 Randomized Double-Blind Double-Dummy Placebo- and Active-Controlled Single-Dose Six-way Crossover Study Evaluating the Abuse Potential of Lyrica Taken Orally with Oxycodone HCl in Healthy Non-Drug Dependent Recreational Opioid Users".
A.6 - To change the ATC Code from N03AX16 to N02BF02."

WS2523
Atectura Breezhaler-
EMEA/H/C/005067/WS2523/0021
Bemrist Breezhaler-
EMEA/H/C/005516/WS2523/0017
Enerzair Breezhaler-
EMEA/H/C/005061/WS2523/0018
Zimbus Breezhaler-
EMEA/H/C/005518/WS2523/0015
Novartis Europharm Limited, Lead Rapporteur: Finbarr Leacy, "Update of sections 5.3 and 6.6 of the SmPC in order to include a statement regarding the risk to the environment based on results from ERA study Mometasone furoate – Fish Sexual Development Test with Zebrafish (Danio rerio). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

WS2534
Abseamed-
EMEA/H/C/000727/WS2534/0104
Binocrit-
EMEA/H/C/000725/WS2534/0103
Epoetin alfa Hexal-
EMEA/H/C/000726/WS2534/0103
Sandoz GmbH, Lead Rapporteur: Alexandre Moreau, "Update of section 4.4 of the SmPC in order to allow for iron supplementation in accordance with patient needs and up-to date treatment guidelines by removing the restrictions to exclusively use the oral route of administration for iron supplementation. In

addition, the MAH took the opportunity to introduce minor editorial changes to the PI, bring it in line with the latest QRD template version 10.3, align it with the reference product and update instructions for use."

B.6.10. CHMP-PRAC assessed procedures

BESPONSA - inotuzumab ozogamicin - EMEA/H/C/004119/II/0026, Orphan
Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer, "Update of sections 4.2, 4.6, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information based on final results from studies ITCC-059 (WI203581) and INO-Ped-ALL-1 (WI235086). Study WI203581 is a Phase 1/2, multicenter, European, multi-cohort, open-label study in pediatric patients (≥1 and <18 years of age) with R/R CD22-positive Acute Lymphoblastic Leukemia (ALL); and study WI235086 is an open-label, multi-center Phase 1 study to assess safety and tolerability of InO in Japanese pediatric patients with R/R CD22-positive ALL. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

Increlex - mecasermin - EMEA/H/C/000704/II/0080
Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, "Update of sections 4.2, 4.6 and 4.8 of the SmPC in order to modify administration instructions recommendation regarding the monitoring of pre-prandial blood glucose in pre-prandial condition and in case of symptoms and to prevent the risk of lipohypertrophy, delete wording in the pregnancy section and update on number of patients with severe primary IGFD based on the cumulative review of safety database, scientific literature and clinical trials data. The Package Leaflet is updated accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0039, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Update of sections 4.8 and 5.1 of the SmPC in order to update information based on final results from study VX17-445-105 (study 105); this is a phase 3, open-label, extension study evaluating the long-term safety and efficacy of ELX/TEZ/IVA treatment in cystic fibrosis (CF) subjects 12 years of age and older, homozygous, or heterozygous for the F508del-CFTR mutation who participated in study VX17-445-102 (study 102) or study VX17-445-103 (study 103). The RMP version 7.2 has also been submitted."

Lenvima - lenvatinib - EMEA/H/C/003727/II/0050

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information based on final results from studies E7080-G000-207 and E7080-G000-230. Study E7080-G000-207 is a multicenter, open-label, Phase 1/2 study of lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma; Study E7080-G000-230 is a multicenter, open-label, randomized Phase 2 study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with Relapsed or Refractory Osteosarcoma (OLIE). The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted."

Lynparza - olaparib - EMEA/H/C/003726/II/0064

AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, "Update of sections 4.8 and 5.1 of the SmPC to update the results of a descriptive analysis of Overall Survival at seven years last subject randomised in study D0818C0001 (SOLO1). This is a Phase III randomised, double blind, placebo controlled, multicentre study in which advanced ovarian cancer patients with BRCA mutations who had responded following first-line platinum-based chemotherapy were randomised 2:1 to receive either Olaparib (300 mg bd, tablet formulation)

or placebo. The RMP version 28 has also been submitted. In addition, the MAH took the opportunity to update section D of Annex II."

Mavenclad - cladribine - EMEA/H/C/004230/II/0027

Merck Europe B.V., Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Inês Ribeiro-Vaz, "Update of sections 4.5 and 4.6 of the SmPC in order to add information regarding the use of mavenclad with oral contraceptives based on the final study results from the drug-drug interaction study (MS 700568-0031). This is a randomized, double-blind, 2-period, 2-sequence, crossover Phase I study with a 1-month run-in period to examine the effect of cladribine tablets on the pharmacokinetics of a monophasic oral contraceptive containing ethinyl estradiol and levonorgestrel (microgynon) in pre-menopausal women with Relapsing Multiple Sclerosis (RMS). The Annex II and Package Leaflet are updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to sections 4.2 and 4.4 of the SmPC."

NINLARO - ixazomib - EMEA/H/C/003844/II/0045, Orphan

Takeda Pharma A/S, Rapporteur: Armando Genazzani, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of the Clinical Study Report (Addendum 2) for study C16019 listed as a Specific Obligation in the Annex II of the Product Information. This is a phase 3, randomized, double-blind, placebo-controlled study of single-agent oral ixazomib as maintenance therapy following autologous stem cell transplant (ASCT) for patients with newly diagnosed multiple myeloma. In addition, the MAH proposes to remove NINLARO from the list of medicines subject to additional monitoring and to remove the black triangle from the SmPC. The Annex II and Package Leaflet are updated accordingly. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet."

TAGRISSO - osimertinib - EMEA/H/C/004124/II/0052

AstraZeneca AB, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst, "Update of section 5.1 of the SmPC in order to update efficacy information (final OS data) based on final results from study D5164C00001 (ADAURA) listed as a PAES in the Annex II; this is a Phase III, double-blind, randomised, placebo-controlled study, designed to assess the efficacy and safety of osimertinib versus placebo in patients with stage IB-IIIA epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC) who have undergone complete tumour resection, with or without postoperative adjuvant chemotherapy. The RMP version 15 has also been submitted. In addition, the MAH took the opportunity to update Annex II section D of the PI and to implement editorial changes to the SmPC."

TEPMETKO - tepotinib - EMEA/H/C/005524/II/0009

Merck Europe B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information based on results from study VISION (MS200095-0022); this is a Phase II, multicenter, open-label, single-arm study to evaluate the efficacy and safety/tolerability of the recommended dose of tepotinib in participants with advanced NSCLC of all histology types who tested positive for METex14 skipping alterations by next-generation sequencing in tissue (RNA-based) or plasma (circulating tumor DNA based). The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."

WS2513
Copalia HCT- EMEA/H/C/001159/WS2513/0106
Dafiro HCT- EMEA/H/C/001160/WS2513/0108
Exforge HCT- EMEA/H/C/001068/WS2513/0105

Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, Lead PRAC Rapporteur: Marie Louise Schougaard Christiansen, "C.I.11.z - to confirm the fulfilment of condition B to the Marketing

Authorisation of Exforge HCT Film-coated Tablets (including its duplicates Dafiro HCT and Copalia HCT) as set out by the Commission Decision in the outcome of the assessment for the impact of Article 5(3) scientific opinion on nitrosamines in human medicinal products on the opinion adopted pursuant to Article 31 of Directive 2001/83/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (attached as annex 1). Annex II of the PI has been amended accordingly."

B.6.11. PRAC assessed procedures

PRAC Led **EVUSHELD - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0013** AstraZeneca AB, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of an updated RMP version 5 succession 1 to remove the commitment to conduct the post-authorisation safety study (PASS) D8850R00006: A post-authorization Observational Study of Women exposed to EVUSHELD During Pregnancy (O-STEREO)."
PRAC Led **Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0063** Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "To update sections 4.3, 4.4 and 4.5 of the SmPC to update and streamline the relevant wording on opioids following the assessment of PSUSA/00010366/202209 procedure. The Package Leaflet is updated accordingly. The RMP version 12.9 has also been submitted."
PRAC Led **Olumiant - baricitinib - EMEA/H/C/004085/II/0043** Eli Lilly Nederland B.V., PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of an updated RMP version 22.1 in order to remove existing additional pharmacovigilance activities (category 3 studies): study I4V-MC-JAJA (JAJA) and study I4V-MC-JAJD (JAJD)."

PRAC Led

Plegridy - peginterferon beta-1A - EMEA/H/C/002827/II/0070

Biogen Netherlands B.V., PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study 105MS401. The objective of this study was to determine the incidence of serious adverse events (SAEs) in patients with relapsing forms of MS in routine clinical practice and to assess the overall long-term clinical effectiveness of peginterferon beta-1a in patients with relapsing forms of MS in routine clinical practice."

PRAC Led

Pravafenix - fenofibrate / pravastatin sodium - EMEA/H/C/001243/II/0034

Laboratoires SMB s.a., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Jean-Michel Race, "Submission of the final report from study POSE: Pravafenix Observational Study in Europe (EUPAS 13661), listed as a category 3 study in the RMP (MEA/007.10). This is an observational, three-year cohort comparative study on the safety of the fixed dose combination pravastatin 40 mg/ fenofibrate 160 mg (Pravafenix) versus statin alone in real clinical practice."

PRAC Led

Stelara - ustekinumab - EMEA/H/C/000958/II/0100

Janssen-Cilag International N.V., PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Update of section 4.6 of the SmPC in order to update information on pregnancy based on the final synoptic report from study CNTO1275PSO4037 (OTIS); this is a pregnancy exposure registry for Stelara. The Package Leaflet is updated accordingly. The RMP version 26.2 has also been submitted."

PRAC Led

Xeljanz - tofacitinib - EMEA/H/C/004214/II/0054

Pfizer Europe MA EEIG, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 31.1 in order to modify study A3921427 from an interventional to a non-interventional study. In addition, the MAH has taken the opportunity to update other sections

of the RMP."

PRAC Led
Xofigo - radium-223 -
EMEA/H/C/002653/II/0052
Bayer AG, PRAC Rapporteur: Rugile Pilviniene, PRAC-CHMP liaison: Vilma Petrikaite, "Submission of the final report from study 20702 listed as a category 3 study in the RMP. This is a non-interventional drug utilisation study to investigate the risk of off-label use."

PRAC Led
WS2486
Emtricitabine/Tenofovir disoproxil Zentiva-
EMEA/H/C/004137/WS2486/0025
Zentiva k.s., Generic, Generic of Truvada, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "C.I.11.z - To update the RMP for Emtricitabine/Tenofovir disoproxil according to reference product update, Truvada (EMEA/H/C/WS2320)."

PRAC Led
WS2535
Entresto-
EMEA/H/C/004062/WS2535/0053
Neparvis-
EMEA/H/C/004343/WS2535/0051
Novartis Europharm Limited, Lead PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "C.I.11.z - To provide a consolidated RMP for Entresto and its duplicate marketing authorisation Neparvis following approval of:
- RMP version 4.2 (EMEA/H/C/004062/X/0044/G for Entresto and EMEA/H/C/004343/X/0042/G for Neparvis)
- RMP version 5.0 (EMEA/H/C/004062/WS2434/G for Entresto and EMEA/H/C/004343/WS2434/G for Neparvis)
- RMP version 6.0 (EMEA/H/C/004062/WS2465 for Entresto and EMEA/H/C/004343/WS2465 for Neparvis)"

PRAC Led
WS2537
Segluromet-
EMEA/H/C/004314/WS2537/0021
Steglatro-
EMEA/H/C/004315/WS2537/0020

Steglujan-
EMEA/H/C/004313/WS2537/0024
Merck Sharp & Dohme B.V., Lead PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "C.I.11.z - To provide a new version of the RMP to update the final study report date for study 8835-062 , following approval of the post-authorisation measure procedure EMEA/H/C/004313-5/MEA/002.5."

PRAC Led
WS2541
Ozempic-
EMEA/H/C/004174/WS2541/0040
Rybelsus-
EMEA/H/C/004953/WS2541/0035
Novo Nordisk A/S, Lead PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "C.I.11.z - To update the RMP following assessment of the same for the reference product Wegovy (EMEA/H/C/005422/II/0009 approved on 28 April 2023). The Semaglutide RMP which is shared with all three Semaglutide products (Rybelsus, Ozempic, Wegovy) was updated due to an extension of the Wegovy label to include an indication in the adolescent population. The RMP's for Rybelsus (oral semaglutide for treatment of Type 2 Diabetes) and Ozempic (sc. semaglutide for treatment of Type 2 Diabetes) have been updated accordingly. Please note that no labelling changes will be made in this procedure because the investigation into efficacy and safety in paediatric population above 10 years of age according to agreed PIPs for Ozempic and Rybelsus is still ongoing."

PRAC Led
WS2546
Brimica Genuair-
EMEA/H/C/003969/WS2546/0039
Duaklir Genuair-
EMEA/H/C/003745/WS2546/0040
Covis Pharma Europe B.V., Lead PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "C.I.11.z - To provide a new version of the RMP to update the milestone for PASS study D6560R00004 regarding Arrythmia final report ."

PRAC Led

WS2548
Bretaris Genuair-
EMEA/H/C/002706/WS2548/0051
Eklira Genuair-
EMEA/H/C/002211/WS2548/0052
Covis Pharma Europe B.V., Lead PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "C.I.11.z - To provide a new version of the RMP to update the milestone for PASS study D6560R00004 regarding Arrythmia final report ."

B.6.12. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel -
EMEA/H/C/004731/II/0026/G, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani

Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0063, ATMP
Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo, "Submission of the final report from study 20110261 listed as a category 3 study in the RMP. This is a Phase I, multi-center, open-label, dose de-escalation study to evaluate the safety and efficacy of talimogene laherparepvec in pediatric subjects with advanced noncentral nervous system tumors that are amenable to direct injection."

Kymriah - tisagenlecleucel -
EMEA/H/C/004090/II/0072, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

Upstaza - eladocagene exuparvovec -
EMEA/H/C/005352/II/0013, Orphan, ATMP
PTC Therapeutics International Limited, Rapporteur: Maura O'Donovan, CHMP Coordinator: Finbarr Leacy

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

PRAC Led
Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0064, ATMP
Amgen Europe B.V., PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of an updated RMP version 11.0 in order to remove the important potential risk of "talimogene laherparepvec-mediated anti-GM-CSF antibody response", based on the accumulated scientific and clinical data."

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2470/G
Ambirix-
EMEA/H/C/000426/WS2470/0129/G
Cervarix-
EMEA/H/C/000721/WS2470/0123/G
Infanrix hexa-
EMEA/H/C/000296/WS2470/0332/G
Twinrix Adult-
EMEA/H/C/000112/WS2470/0164/G
Twinrix Paediatric-
EMEA/H/C/000129/WS2470/0165/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2494/G
Ozempic-
EMEA/H/C/004174/WS2494/0039/G
Wegovy-
EMEA/H/C/005422/WS2494/0013/G
Novo Nordisk A/S, Lead Rapporteur: Johann Lodewijk Hillege

WS2506/G
Filgrastim Hexal-
EMEA/H/C/000918/WS2506/0073/G
Zarzio-
EMEA/H/C/000917/WS2506/0074/G
Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege

WS2511/G
Entresto-
EMEA/H/C/004062/WS2511/0052/G
Neparvis-

EMEA/H/C/004343/WS2511/0050/G
Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege

WS2514
Herceptin-
EMEA/H/C/000278/WS2514/0190
MabThera-
EMEA/H/C/000165/WS2514/0198
Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2516
Revatio-
EMEA/H/C/000638/WS2516/0105
Viagra-EMEA/H/C/000202/WS2516/0118
Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege

WS2521
Riltrava Aerosphere-
EMEA/H/C/005311/WS2521/0007
Trixeo Aerosphere-
EMEA/H/C/004983/WS2521/0014
AstraZeneca AB, Lead Rapporteur: Finbarr Leacy, "C.I.z - To submit the new results for the conducted fish full life-cycle study for budesonide and an updated Environmental Risk Assessment (ERA) report."

WS2524
Galvus-EMEA/H/C/000771/WS2524/0079
Jalra-EMEA/H/C/001048/WS2524/0082
Xiliarx-EMEA/H/C/001051/WS2524/0080
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "C.I.z - To provide an updated Environmental Risk Assessment (ERA) report for OECD TG308 and OECD TG218 studies."

WS2528/G
Eucreas-
EMEA/H/C/000807/WS2528/0101/G
Icandra-
EMEA/H/C/001050/WS2528/0106/G
Zomarist-
EMEA/H/C/001049/WS2528/0103/G
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "C.I.z - To provide the Environmental Risk Assessment (ERA) report for vildalgiptin to add data from OECD TG308 and OECD TG218 studies.
C.I.z - To provide the Environmental Risk Assessment (ERA) report for metformin to add

FOCUS_DEGKINv2 SFO calculated DT50 values.”
WS2530 **Filgrastim Hexal-** **EMEA/H/C/000918/WS2530/0072** **Zarzio-EMEA/H/C/000917/WS2530/0073** Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege, “C.I.2.a - To update the Product information of Zarzio and Filgrastim Hexal in line with the reference product, Neupogen, following the detection of discrepancies during a full review. Furthermore, the MAH is taking the opportunity to implement the ‘Excipients in the labelling and package leaflet of medicinal products for human use’ guideline (SANTE- 2017-11668) (EMA/CHMP/302620/2017 Rev. 2; 12.09.2022) regarding the excipient “Sodium”; and update the Instruction for Use (IFU) to include a warning about dropping the product.”
WS2536 **Rixathon-** **EMEA/H/C/003903/WS2536/0067** **Riximyo-** **EMEA/H/C/004729/WS2536/0068** Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus
WS2539 **Lantus-EMEA/H/C/000284/WS2539/0128** **Suliqua-EMEA/H/C/004243/WS2539/0034** **Toujeo-EMEA/H/C/000309/WS2539/0124** Sanofi-Aventis Deutschland GmbH, Lead Rapporteur: Kristina Dunder

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended

F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 17-20 July 2023 CHMP plenary:

Neurology	
Treatment of narcolepsy with cataplexy	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Treatment of Alzheimer's Disease (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Endocrinology-Gynaecology-Fertility-Metabolism	
RP-L301 Treatment of pyruvate kinase deficiency ATMP	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Infectious Diseases	
Prevention of pneumococcal disease	The CHMP denied eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in July 2023 for August 2023 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address